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Regulation of replicative immortality by GABPβ1L in TERT promoter mutant 
glioblastoma 
 
Andrew G. Mancini 
 
ABSTRACT 
 
 Telomeres are repetitive sequences of DNA that protect the ends of 
chromosomes and are gradually lost each cycle of cell division. In cells such as stem 
cells and germ cells, telomeres are indefinitely maintained through the use of the 
enzymatic complex telomerase. In order to achieve replicative immortality and form a 
tumor, cancer cells must find a way to replenish telomeres early on during 
tumorigenesis. The most common way that cancer cells enable immortality is by 
reactivating expression of the catalytic subunit, Telomerase Reverse Transcriptase 
(TERT), which is normally silenced in somatic cells. Activating mutations in the promoter 
region of TERT gene are the most common mechanism through which tumor cells 
reactivate telomerase, allowing for indefinite telomere maintenance and enabling 
cellular immortalization. These mutations specifically recruit the multimeric ETS factor 
GABP, which can form two functionally independent transcription factor species – a 
dimer or a tetramer.  
 We have identified GABPβ1L, the tetramer-forming isoform of GABP that is 
dispensable for normal development, as being specifically recruited to the mutant TERT 
promoter in glioblastoma cells. We show that genetic disruption of GABPβ1L results in 
TERT silencing in a TERT promoter mutation-dependent manner. Reducing TERT 
expression by disrupting GABPβ1L culminates in telomere loss and cell death through 
exclusively in TERT promoter mutant cells. Orthotopic xenografting of GABPβ1L-
reduced, TERT promoter mutant glioblastoma cells rendered lower tumor burden and 
	 x	
longer overall survival in mice. These results highlight the critical role of GABPβ1L in 
enabling immortality in TERT promoter mutant glioblastoma. 
 TERT promoter mutations are the third most common mutation in human cancer, 
and the single most common mutation in glioblastoma. Understanding how the promoter 
mutation leads to tumor cell immortality could uncover potential targets to undermine 
immortality and reduce tumor growth. TERT promoter mutations selectively recruit the 
transcription factor GABP to activate TERT expression across multiple types of cancer. 
Our results suggest that the normally dispensable GABPβ1L isoform of GABP is a key 
to tumor cell immortality in TERT promoter mutant brain tumors. Therefore, inhibiting 
GABPβ1L may be an approach to reverse tumor cell immortality while sparing TERT 
promoter wild-type cells. 
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1.1 TELOMERES AND TELOMERASE 
 
Telomeres are a highly regulated complex of tandem ‘TTAGGG’ repeats and 
their associated proteins at the ends of each chromosome (Blackburn et al., 2006; 
Counter et al., 1992). Telomeres maintain DNA integrity by protecting or “capping” the 
ends of chromosomes, but progressively shorten with each cell division due to lagging-
strand synthesis (Chin et al., 1999; Fitzgerald et al.; 1999). Normal human cells have 
chromosomes with telomeres ranging from 3 kilobases to 10 kilobases in length, with 
significant heterogeneity in telomere length existing between individual cells and even 
individual chromosomes (Blackburn et al., 2006). In somatic cells that cannot replenish 
their telomeres, telomeres endow the cell with a finite lifespan that limits the amount of 
times the cell can divide (Kim et al., 1994; Shay and Wright, 2000). When a telomere 
reaches a critically short length, the protein components of the telomere can no longer 
stably bind to and protect the end of the chromosome (Capper et al., 2007; der-
Sarkissian et al., 2004; Blackburn et al., 2006). The loss of the telomere protein cap 
allows the de-protected chromosome to be recognized by DNA damage repair 
machinery as a double stranded break, thus triggering TP53- and Rb-dependent cell 
cycle arrest and senescence (Saretzki et al., 1999; Whitaker et al., 1995). 
However, certain cells such as stem cells and germ cells can maintain telomere 
length indefinitely by replenishing lost telomeric repeats using the telomerase enzymatic 
complex (Bryan and Cech, 1999; Counter et al., 1998). Telomerase is an RNA-
dependent DNA polymerase that counteracts telomere attrition in stem cells and germ 
cells, thereby allowing these cells to achieve a state of “immortalization” and replicate 
indefinitely (Kim et al., 1994; Shay and Wright, 2000). The telomerase complex is 
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composed of the non-coding RNA template TERC and the catalytic subunit Telomerase 
Reverse Transcriptase (TERT) along with additional scaffolding and auxiliary proteins 
(Bryan and Cech, 1999; Counter et al., 1998). The transcriptional regulation of the 
telomerase reverse transcriptase (TERT) gene is a rate-limiting step in modulating 
telomerase activity in non-germ cells (Bryan and Cech, 1999; Counter et al., 1998). For 
example, in somatic cells TERT expression is silenced and therefore telomerase activity 
is absent. In contrast, the majority of stem cells exhibits robust expression of TERT and 
therefore possesses high levels of telomerase activity (Kim et al., 1994; Shay and 
Wright, 2000).  
 
 
1.2 IMMORTALITY IN CANCER 
Similar to stem cells and germ cells, tumor cells must too find a way to overcome 
telomere shortening in order to continue to proliferate and achieve immortality (Chin et 
al., 1999; Kim et al., 1994; Shay and Wright, 2000). The acquisition of replicative 
immortality during tumorigenesis can be found across all human tumors regardless of 
tissue of origin (Vinagre et al. 2013; Killela et al. 2013). The enabling of replicative 
immortality in cancer is typically an early event during tumor evolution, acting as a 
“gateway event” that can predispose tumor cells to further tumorigenic events, such as 
mutations in tumor suppressors or oncogenes (Chiba et al., 2017; Counter et al., 1992; 
Hackett et al., 2001). In the absence of TP53, terminal telomere shortening results in 
spontaneous telomere fusions, causing massive cell death (der-Sarkissian et al., 2004; 
Saretzki et al., 1999; Whitaker et al., 1995). Cells that emerge from this period of crisis 
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have acquired genomic instability and cellular immortalization, fundamental features of 
human tumors (Hackett et al., 2001).  
Although normally silenced in somatic cells, TERT is aberrantly expressed in 
90% of aggressive cancers, highlighting this as a hallmark of tumorigenesis (Chin et al., 
1999; Kim et al., 1994; Saretzki et al., 1999; Shay and Wright, 2000). Reactivating 
telomerase enables cells with finite lifespan to achieve limitless proliferative potential 
and bypass cellular senescence induced by DNA replication-associated telomere 
shortening (Meyerson et al., 1997). Several mechanisms of TERT gene re-activation 
have been previously described across a breadth of cancer types. These mechanisms 
include activation via epigenetic mechanisms, activation via oncogenic signaling (e.g. 
MYC-mediated activation or WNT-mediated activation), TERT gene amplification, TERT 
structural variation, and TERT promoter mutation (Ohba et al., 2016; Horn et al., 2013; 
Huang et al., 2013; Ceccarelli et al., 2016). In order to re-activate telomerase and 
achieve immortality, a tumor cell typically uses only one of these mechanisms to re-
express or amplify a single allele of the TERT gene.  
Understanding mechanisms of aberrant TERT expression represents a crucial 
outstanding problem in cancer research. Reversal of immortalization is a largely 
unexplored but potentially valuable therapeutic approach to treating cancer. However, 
previous attempts to inhibit telomerase in human cancer have largely failed due to off-
target toxicities associated with reversing immortality in non-tumor cells such as 
hematopoietic stem cells (Shay and Wright, 2006). Therefore, inhibition of telomerase 
through targeted disruption of one or more of these mechanisms of TERT re-expression 
may represent a promising avenue for tumor-specific inhibition of replicative immortality. 
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1.3 TERT PROMOTER MUTATIONS IN GLIOBLASTOMA 
 
Non-coding mutations in the TERT promoter are the third most common somatic 
mutation in human cancer, revealing a potentially causal biological mechanism driving 
increased telomerase activity in tumors (Arita et al., 2013; Killela et al., 2013; Zehir et 
al., 2017). Initially discovered in cutaneous melanoma, TERT promoter mutations have 
since been identified in over fifty types of human cancers (Huang et al., 2013; Horn et 
al., 2013; Zehir et al., 2017). These mutations occur primarily in cancers hypothesized 
as arising from cell populations with low levels of self-renewal, such as hepatocytes or 
keratinocytes (Killela et al., 2013). Specifically, one of two positions in the TERT 
promoter, G228A or G250A, is mutated in many adult and pediatric CNS tumors, 
including 83% of primary IDH WT GBM and 80-97% of OD, making them the most 
recurrent single-nucleotide mutations observed in these cancer types (Vinagre et al., 
2013; Arita et al., 2013; Killela et al., 2013; Zehir et al., 2017).  
Both mutations are associated with increased TERT expression and telomerase 
activity, and have prognostic power in GBM (Spiegl-Kreinecker et al., 2015; Vinagre et 
al., 2013). These two TERT promoter mutations are nearly always mutually exclusive, 
heterozygous, and arise early on during tumorigenesis (Horn et al. 2013; Huang et al. 
2013; Killela et al., 2013). Furthermore, in tumor cells bearing TERT promoter 
mutations, these mutations are necessary – albeit not sufficient – for achieving 
replicative immortality (Chiba et al., 2015; Chiba et al., 2017). Both G>A transitions 
generate an identical 11bp sequence that was hypothesized to generate a de novo 
binding site for an ETS transcription factor (Horn et al., 2013; Bell et al. 2015). Despite 
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these compelling findings and the importance of TERT in human cancer, the precise 
function of the mutations had remained elusive. 
 
1.4 GABP-MEDIATED REGULATION OF THE MUTANT TERT PROMOTER 
 
  We identified the functional consequence of these mutations to be recruitment of 
the ETS family transcription factor GA-binding protein (GABP) specifically to the mutant 
promoter (Bell et al., 2015). The cancer-specific interaction of GABP with the TERT core 
promoter mutations highlights a common mechanism utilized by many cancers to 
overcome replicative senescence (Bell et al., 2015; Stern et al., 2015; Makowski et al.; 
2016). Although many ETS transcription factors can bind similar DNA sequence motifs, 
GABP is unique among all ETS factors in that it is an obligate multimer consisting of the 
DNA-binding GABPα subunit and trans-activating GABPβ subunit (Rosmarin et al., 
2004; Sawada et al., 1994). GABP can act as a heterodimer (GABPαβ) composed of 
one GABPα and one GABPβ subunit or a heterotetramer (GABPα2β2) composed of two 
GABPα and two GABPβ subunits (de la Brousse et al., 1994; Rosmarin et al., 2004).  
Two distinct genes encode the GABPβ subunit: the GABPB1 gene encoding 
GABPβ1 and the GABPB2 gene encoding GABPβ2. The GABPβ1 subunit has two 
distinct isoforms, a short GABPβ1S isoform and a longer GABPβ1L isoform, while the 
GABPβ2 subunit has a single isoform. Whereas the GABPβ1S isoform is only able to 
dimerize with GABPα, both GABPβ1L and GABPβ2 possess a C-terminal leucine-
zipper domain (LZD) that mediates the tetramerization of two GABPαβ heterodimers (de 
la Brousse et al., 1994; Rosmarin et al., 2004). Although GABPβ1L or GABPβ2 can 
form the GABP tetramer, GABP tetramers containing only the GABPβ1L isoform are 
functionally distinct from GABPβ2-containing tetramers and may control separate 
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transcriptional programs (Jing et al., 2008; Yu et al., 2012). Furthermore, while 
abolishing full GABP function results in early embryonic lethality in mice (Yu et al., 
2012), inhibition of the GABβ1L-only tetramer-specific transcriptional program has 
minimal phenotypic consequences in a murine system (Jing et al., 2008; Xue et al., 
2008). Thus, if the GABP tetramer-forming isoforms are necessary to activate the 
mutant TERTp, targeting these isoforms may be a viable therapeutic approach to 
selectively inhibit TERT and reverse replicative immortality in TERTp mutant cancer.  
 However, it is currently unclear whether the GABP tetramer-forming isoforms are 
necessary to activate the mutant TERT promoter or whether the GABP dimer is 
sufficient. Two proximal GABPα binding sites are required to recruit a GABPα2β2 
tetramer, and, interestingly, the TERT promoter has native ETS binding sites upstream 
of the hotspot mutations that are required for robust activation of the mutant promoter 
(Bell et al., 2015). These native ETS binding sites are located approximately three and 
five helical turns of DNA away from the C228T and C250T mutation sites, respectively, 
which is consistent with the optimal spacing for the recruitment of the GABP tetramer 
(Bell et al., 2015; Chinenov et al., 2000; Yu et al., 1997). Here we tested the hypothesis 
that the C228T and C250T hotspot promoter mutations recruit the tetramer-specific 
GABP isoforms to the mutant TERT promoter to enable telomere maintenance and 
replicative immortality. 
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2.1 ABSTRACT 
 
 Single point mutations in the promoter region of the Telomerase Reverse 
Transcriptase (TERT) gene reactivate TERT expression and telomerase activity in 
cancer cells that bear them. These mutations create a consensus binding site for the 
multimeric ETS transcription factor GABP, allowing GABP to specifically bind to and 
activate the mutant TERT promoter either as a dimer or as a tetramer. Here, we show 
that genetic disruption of GABPβ1L, a tetramer-forming isoform of GABP that is 
dispensable for normal development, results in TERT silencing in a TERT promoter 
mutation-dependent manner. RNAi-mediated and LNA-ASO-mediated transient 
knockdown of GABPβ1L ubiquitously reduced TERT expression across a panel of 
TERT promoter mutant glioma lines, but had no effect in TERT promoter wild-type lines. 
Furthermore, reduction of GABPβ1L tetramerization ability via CRISPR-Cas9-mediated 
disruption of GABPB1L was sufficient to reduce GABP occupancy at the mutant TERT 
promoter as well as TERT expression exclusively in TERT promoter mutant lines. 
These data support GABPβ1L as the GABP isoform responsible for activating the 
mutant TERT promoter in glioblastoma. 
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2.2 THE GABP TETRAMER-FORMING ISOFORM GABPβ1L POSITIVELY 
REGULATES TERT EXPRESSION SOLELY IN TERT PROMOTER MUTANT TUMOR 
CELLS 
 To determine if the GABP dimer-forming isoform (GABPβ1S) or the tetramer-
forming isoforms (GABPβ1L and GABPβ2) regulate the mutant TERT promoter, we 
performed gene knockdown experiments in vitro and expression correlation analysis in 
primary tumors. We used siRNA-mediated knockdown of GABPβ1 - affecting GABPβ1S 
and GABPβ1L - and GABPβ2 in three TERT promoter mutant glioma cell lines, six early 
passage primary cultures and five TERT promoter wild-type and TERT expressing cell 
lines. Knockdown of GABPβ1 significantly reduced TERT expression in eight of nine 
TERT promoter mutant cell cultures, but had limited effect in the TERT promoter wild-
type cultures (Figure 1A). In contrast, siRNA-mediated knockdown of GABPβ2 had a 
less robust and more variable effect on TERT expression in TERT promoter mutant 
cells (Figure S1A). 
 We also tested whether the expression of TERT correlates with expression of 
specific GABP isoforms in clinical samples, including TERT promoter mutant GBMs and 
oligodendrogliomas. This analysis revealed a significant positive monotonic association 
between TERT and GABPB1L mRNA in both cancer types (Figure 1B), but no 
significant correlation between TERT and GABPB1S (Figure 1B) or GABPB2 (Figure 
S1B) mRNA levels. Analysis of GABP isoform and TERT expression data in the 
predominantly TERT promoter wild-type colorectal cancer revealed no positive 
correlation between TERT expression and GABPB1L or GABPB2 expression, although 
a positive correlation between TERT expression and GABPB1S expression was found 
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(Figure S1C). Due to the significant positive correlation between GABPB1L expression 
and TERT expression in glioma, we specifically looked for depletion of the tetramer-
forming GABPB1L isoform mRNA in our β1 knockdown study and confirmed that this 
isoform mRNA was significantly depleted after siRNA-mediated knockdown in 13 of 14 
cell lines (Figure 1C). 
 We further explored this potential dependence on the GABPβ1L isoform for 
activation of the mutant TERT promoter by directly knocking down GABPβ1L with a 
degradation-inducing Locked Nucleic Acid Anti-Sense Oligonucleotide (LNA-ASO) 
targeted to the GABPB1L-exclusive 3’ UTR of the GABPB1 transcript. This LNA-ASO 
specifically depleted GABPB1L transcript levels with no reduction in GABPB1S 
transcript levels (Figure S1D). LNA-ASO-mediated knockdown of GABPβ1L reduced 
TERT expression across all TERT promoter mutant cultures and had no effect on TERT 
expression in all TERT promoter wild-type cultures (Figure 1D). Taken together, these 
data support that the GABP tetramer-forming isoform GABPβ1L positively regulates 
TERT expression in TERT promoter mutant glioma. 
 
2.3 CRISPR-CAS9-MEDIATED DISRUPTION OF GABPB1L REDUCES GABP-
MEDIATED ACTIVATION OF THE MUTANT TERT PROMOTER 
  We then directly tested the necessity of GABPβ1L for mutant TERT promoter 
activation by generating clones with reduced GABPβ1L function from three of the 
aforementioned TERT promoter mutant GBM cell lines (GBM1, T98G, and LN229) and 
three TERT promoter wild-type control cell lines (NHAPC5, HCT116 and HEK293T) 
using nuclease-assisted vector integration (NAVI) CRISPR-Cas9 editing (Brown et al., 
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2016; Gapinske et al., 2018) (Figure 2A). We isolated two independent GABPB1L-
edited clones (C1 and C2) and one isogenic CRISPR control clone (CTRL) for each 
parental line using one of two non-overlapping sgRNAs targeting GABPB1 exon 9 or a 
sgRNA targeting an intergenic region of chromosome 5, respectively (Figure S2A and 
Table S1). GABPB1 exon 9 contains the coding sequence for the LZD, and disruption of 
this exon is sufficient for ablation of the GABPβ1L-containing tetramer while leaving 
GABPβ1S intact (Chinenov et al., 2000; Sawada et al., 1994). Each GABPB1L-edited 
clone had the disruption of at least one allele via integration of a puromycin or 
hygromycin resistance cassette with most remaining GABPB1L alleles containing indels 
in the LZD (Figure S2B and Table S2). Analysis of cassette integration and locus 
integrity at predicted off-target cutting sites in coding regions (Hsu et al., 2013) via PCR 
and Surveyor assay, respectively, showed no aberrations outside the target regions 
(Figures S3A-F). GABPB1L-edited clones had reduced GABPβ1L protein levels with no 
measurable reduction in β1S levels, further confirming the specificity of our editing 
approach (Figure S3G). 
 We next examined whether the indels in the remaining GABPB1L alleles (Figure 
S2B) were sufficient to generate GABPβ1L protein with reduced tetramerization activity. 
Using PCR-mediated site-directed mutagenesis, we replicated three mutations (Table 
S3) in GABPB1L and assayed the ability of the mutant GABPβ1L to form the GABP 
tetramer (Figure 2B). DEL1 and DEL2 are in-frame deletions in the GABPB1L LZD-
coding region and DEL3 is a putative loss-of-function frame-shift mutation in the same 
domain (Figure S2B). Each of the tested mutations reduced the ability of GABPβ1L to 
form the tetramer compared to the wild-type control, thereby indicating that the 
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CRISPR-Cas9-induced mutations in the GABPB1L LZD-coding region are sufficient to 
produce variants of the GABP tetramer-forming isoform GABPβ1L with reduced 
function. Thus, all GABPB1L-edited clones will be referred to as “GABPβ1L-reduced” to 
encompass reductions in both protein levels and protein function. 
 Chromatin immunoprecipitation of GABP followed by quantitative PCR (qPCR) at 
the mutant TERT promoter revealed the loss of GABP binding in the GABPβ1L-reduced 
TERT promoter mutant clones compared to the control lines (Figure 2C). Furthermore, 
analysis of TERT expression via RT-qPCR confirmed a significant reduction in - but not 
complete loss of - TERT mRNA across all TERT promoter mutant clones, whereas no 
decreases in expression were detected in clones from TERT promoter wild-type cells 
(Figure 2D). Additionally, overexpression of exogenous GABPβ1L in each GABPβ1L-
reduced clone was sufficient to rescue both TERT expression (Figures 2E and S3H) 
and GABP binding at the mutant TERT promoter (Figure 2F). Taken together, these 
data confirm that the GABP tetramer-forming isoform GABPβ1L is necessary for the 
complete activation of the mutant TERT promoter. 
 
2.4 GABPβ1L REGULATES A SUBSET OF GABP TRANSCRIPTION FACTOR 
TARGETS IN GBM CELLS 
 We next explored whether canonical GABP target genes are affected at the 
expression level after inhibition of GABPβ1L function. The four targets selected for 
preliminary expression analysis (COXIV, EIF6, RPS16, and TFB1M) are essential for 
cell growth and have been previously identified to recruit the GABPβ1L-containing 
GABP tetramer via two ETS binding sites in their promoter (Carter and Avadhani, 1994; 
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Donadini et al., 2006; Genuario and Perry, 1996; Yang et al., 2014). SKP2 contains only 
one ETS binding site in its promoter and should be unaltered by changes in GABPβ1L 
(Yang et al., 2007). We identified minimal differences in the expression of each of the 
five targets between the CRISPR control and GABPβ1L-reduced clones (Figure 3A). 
 To further interrogate the effects of GABPβ1L reduction on global gene 
expression, we performed RNA sequencing (RNA-seq) for our TERT promoter mutant 
CRISPR control and GABPβ1L-reduced lines 45 days post-editing (Figure 3B and Table 
S4). We identified 161 transcripts, including TERT, differentially expressed (DE; 
FDR<0.05) after GABPβ1L reduction that were common to all three TERT promoter 
mutant lines. A majority of these DE transcripts (55%) were transcribed from genes with 
GABP-bound promoters, as determined from ENCODE ChIP-seq data from TERT 
promoter wild-type and mutant cancer cell lines (see STAR Methods). Interestingly, 
however, the vast majority (99%) of GABP-bound genes were not differentially 
expressed between the control and β1L-reduced lines. Gene ontology analysis of these 
DE transcripts identified enrichment in genes involved in development, cell-to-cell 
signaling, and proliferation (Figure 3C and Table S5). This global transcriptional 
analysis further validates that we have significantly inhibited the function of GABPβ1L in 
the GABPβ1L-reduced cell lines. These data, in combination with our qPCR analysis of 
canonical GABP tetramer targets, supports previous studies delineating specific 
transcriptional programs that different GABP species may control (Jing et al., 2008; Xue 
et al., 2008; Yu et al., 2012). The basis for the differential sensitivity between the effects 
of disrupting GABPβ1L function on the mutant TERT promoter and selected down-
regulated GABP loci relative to other GABP targets is unknown, but may be due to 
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compensation by GABPβ1S, GABPβ2, or other ETS factors at certain GABP binding 
sites and not at other sites, or due to cell type specific differences in the GABP 
transcriptional program. These data suggest that the GABP binding site created by 
mutations in the TERT promoter and a subset of GABP binding sites are more sensitive 
to inhibition of the GABPβ1L-containing GABP tetramer, while other GABP-bound sites 
are less sensitive. 
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2.5 MAIN FIGURES 
 
 
 
Figure 1. The GABP tetramer-forming isoform GABPβ1L positively regulates 
TERT expression solely in TERT promoter mutant tumor cells.  
	 17 
(A) TERT expression following siRNA-mediated knockdown of GABPβ1 (siGABPB1) in 
TERT promoter mutant (left) or TERT promoter-wild-type (right) cell lines and primary 
cultures. *p value<0.05, **p value<0.01, two-sided Student’s t-test compared to a non-
targeting siRNA control (siCTRL) in each respective line.  
(B) Correlation of GABPB1L (top graphs) or GABPB1S (bottom graphs) expression 
(log2[RSEM normalized counts]) versus TERT expression (log2[RSEM normalized 
counts]) from 109 TERT-expressing GBMs (left graphs) or 49 TERT promoter-mutant 
oligodendrogliomas (right graphs). Red line indicates trend line. Black points indicate 
Sanger-validated TERT promoter mutant GBM and oligodendroglioma samples, teal 
points are GBM samples that were not tested for TERT promoter mutation status. 
Spearman’s Rank-Order Correlation was used to generate Spearman rho and p values 
for each correlation.  
(C) GABPB1L expression following siRNA-mediated knockdown of GABPβ1 
(siGABPB1) in TERT promoter mutant (left) and wild-type (right) lines. *p value<0.05, 
**p value<0.01, two-sided Student’s t-test compared to a non-targeting siRNA control 
(siCTRL) in each respective line.  
(D) TERT expression following LNA-ASO knockdown of GABPβ1L (LNA-GABPB1L) in 
TERT promoter mutant (left) or wild-type (right) cell lines and primary cultures compared 
to a control LNA-ASO (LNA-CTRL). *p value<0.05, **p value<0.01, two-sided Student’s 
t-test compared to LNA-CTRL in each respective line. Values are mean ± S.D. of at 
least three independent experiments (A, C, and D; two independent experiments for 
SF10417).  
See also Figure S1. 
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Figure 2. CRISPR-Cas9-mediated disruption of GABPB1L reduces GABP-
mediated activation of the mutant TERT promoter.  
(A) Exon structure for the GABPB1 locus, depicting the GABPB1S and GABPB1L 
isoforms. Inset shows targeting strategy for CRISPR-Cas9 editing of GABPB1L. Red 
blocks indicate sgRNA target sites. Red arrows and dashed lines indicate primer 
locations and target amplicon for PCR validation of editing.  
(B) Quantification of GABPβ1L tetramerization in the wild-type (POS) or mutated 
(DEL1-3) state. The negative (NEG) state consists of one GABPβ1L vector and one 
GABPβ1S vector, the products of which are unable to form a tetramer. *p value<0.05, 
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**p value<0.01, two-sided Student’s t-test of DEL1-3 or NEG respective to the positive 
control (POS).  
(C) GABPα or IgG control ChIP-qPCR for the TERT promoter in CRISPR control 
(CTRL) or β1L-reduced clones (C1 and C2). *p value<0.05, **p value<0.01, two-sided 
Student’s t-test compared to respective CTRL.  
(D) TERT expression relative to CTRL for GABPβ1L-reduced TERT promoter mutant 
(left) or wild-type (right) clones. *p value<0.05, **p value<0.01, two-sided Student’s t-
test compared to CTRL.  
(E,F) TERT expression (E) or GABPα occupancy (F) in GABPβ1L-reduced clones 
relative to CTRL 48 hr following transfection with empty (VECTOR) or GABPβ1L 
expression vector. *p value<0.05, **p value<0.01, two-sided Student’s t-test compared 
to respective VECTOR control.  
Values are mean ± S.D. of at least two independent experiments (C and F) or three 
independent experiments (B, D, and E).  
See also Figures S2-S3 and Tables S1-S3. 
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Figure 3. GABPβ1L regulates a subset of GABP transcription factor targets in 
GBM cells.  
(A) Expression of one GABP dimer target and four GABP tetramer targets relative to 
CTRL for GABPβ1L-reduced clones derived from TERT promoter mutant and wild-type 
lines at day 45 post-editing. *p value<0.05, **p value<0.01, two-sided Student’s t-test 
compared to CTRL. Values are mean ± S.D of at least three independent assays.  
(B) Volcano plot of expression differences between CTRL and GABPβ1L-reduced 
TERT promoter mutant lines (GBM1, T98G, and LN229) as determined via RNA-seq at 
day 45 post-editing. Maroon-colored points represent putative GABP-regulated genes 
that are differentially expressed (log2 Fold Change>1 & FDR<0.05).  
(C) GO-terms analysis of 161 genes that are commonly differentially expressed genes 
between CTRL and multiple GABPβ1L-reduced TERT promoter mutant lines.  
See also Tables S4 and S5. 
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2.6 SUPPLEMENTAL FIGURES 
 
 
 
Figure S1, related to Figure 1. GABPβ1S and GABPβ2 do not robustly positively 
regulate TERT in TERT promoter mutant cancer with intact GABPβ1L.  
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(A) TERT expression following siRNA-mediated knockdown of GABPβ2 (siGABPB2) in 
TERT promoter mutant (left) or wild-type (right) cell lines and primary cultures. *p 
value<0.05, two-sided Student’s t-test compared to a non-targeting siRNA (siCTRL) in 
each respective line.  
(B,C) Correlation of GABPB1L, GABPB1S, or GABPB2 mRNA expression (log2[RSEM 
normalized counts]) versus TERT mRNA expression (log2[RSEM normalized counts]) 
from 109 TERT-expressing GBMs and 49 TERT promoter-mutant oligodendrogliomas 
(B) and 262 TERT-expressing colorectal cancers (C). Red line indicates trend line. 
Spearman’s Rank-Order Correlation was used to generate Spearman’s rho and p 
values for each monotonic correlation.  
(D) GABPB1L and GABPB1S expression following LNA-ASO knockdown of β1L (LNA-
GABPB1L) in TERT promoter mutant (left) or wild-type (right) cell lines and primary 
cultures compared to an LNA-ASO control (LNA-CTRL). *p value<0.05, **p value<0.01, 
two-sided Student’s t-test compared to LNA-CTRL in each respective line.  
All values are mean ± S.D. of at least three independent experiments (two independent 
experiments for SF10417 line). 
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Figure S2, related to Figure 2. Validation of CRISPR-Cas9 editing.  
(A) UV images of successful integration of the targeting vector (~1.1kb for forward 
integration, ~1.3kb for reverse integration) into exon 9 of GABPB1 for the lines used in 
this study.  
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(B) Sanger sequencing of GABPB1 exon 9 showing indels in alleles without targeting 
vector integration for each GABPβ1L-reduced clone. DEL1, DEL2, and DEL3 denote 
deletions induced in Figure 2B. 
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Figure S3, related to Figure 2. Validation of GABPβ1L protein reduction and 
analysis of potential off-target mutations introduced by CRISPR-Cas9 editing.  
	 26 
(A) PCR analysis for potential non-specific integration of the targeting vector at off-
target coding regions for the universal sgRNA.  
(B) On-target integration of the targeting vector at the negative control locus.  
(C) Surveyor analysis to detect potential mutations introduced by CRISPR-Cas9 at 
coding sequences for all sgRNAs. Arrows indicate expected size of fragments from 
Surveyor assay if mutations are present.  
(D-F) PCR analysis for potential non-specific integration of the targeting vector at off-
target coding regions for GABPB1L sgRNA-2 (D), GABPB1L sgRNA-1 (E) and control 
sgRNA (F).  
(G) Immunoblotting for GABPβ1 with GABPβ1L isoform (top, upper marked band) and 
GABPβ1S isoforms (top, lower marked bands) compared to a Cyclophilin B loading 
control (bottom) in all CRISPR-Cas9-edited cell lines. Asterisk (*) designates non-
specific bands.  
(H) GABPB1L expression in GABPβ1L-reduced clones relative to CTRL 48 hr following 
transfection with empty vector (VECTOR) or GABPβ1L expression vector. **p 
value<0.01, two-sided Student’s t-test compared to respective VECTOR control.  
Values are mean ± S.D. of three independent experiments. 
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2.7 SUPPLEMENTAL TABLES 
 
Table S1, related to Figure 2. sgRNA sequences, targets, and PCR primers used 
for CRISPR-Cas9 editing. 
 
Target Location Guide 1 Guide 2 PCR1-F PCR1-R 
GABP
B1L 
chr15:50,57
0,420-
50,571,910 
GCAGCTCC
TAAAGAAA
GAAC 
AGAGGCCT
ACAGACAG
AAGT 
TGTGGAGCA
CAAAATTAG
GG 
CAAGATTGT
ATTCTTTCTT
GACCAAA 
CTRL 
chr5:100,58
7,609-
100,590,53
5 
ATAATAATA
CGTACAGG
CCC  
GGTTCCTTC
AGTACCCAT
GC 
TCATACTTCC
GGCTTTGGA
G 
Univer
sal  
ACCGGGTC
TTCGAGAA
GACC   
TGCCCTTGT
CTTGTAGTTT
CC 
      Off-
Target 
Locus      
GABP
B2 
chr1:151,07
0,578-
151,125,54
2 
  
CACCGCTCC
TGGCCTGTC
TTTT 
GAGGCTCTG
TGGTCCCTG
CTGA 
CNBD
2 
chr20:35,95
4,564-
36,030,700   
GGAGTGGA
GTGGAGCTC
TTGCC 
GGGTCCCTC
CTTTGTGCC
ATGC 
CDK5
RAP2 
chr9:120,38
8,869-
120,580,17
0 
  
TCCTGAAGG
TGGTGCTCT
CT 
TGTGTGTGT
GTTCGCATT
CA 
HOXC 
chr12:53,98
1,509-
53,985,519   
CCACAGTGG
GGCTCAAGC
TGTG 
GCTTCTGGG
GTGTGTTGA
GGGC 
IQCJ-
SCHIP
1 
chr3:158,96
2,928-
159,266,30
7 
  
TCTTATGCC
GCAGCCTAT
TT 
AGTCAAGTG
ACAGAATCC
ACTGT 
SETD1
B 
chr12:121,8
04,180-
121,832,58
4 
  
GGCACAGC
GGCGAACTT
CTCTT 
TTGCAAACC
ACTCTGGGG
CTGG 
ADAM
TS13 
chr9:133,41
4,358-
133,459,40
2 
  
GGCAGGCA
CTTTTGTCA
CCCCA 
CCCCACCTT
GGCTGTGTG
GTAC 
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Target Location Guide 1 Guide 2 PCR1-F PCR1-R 
TSHZ1 
chr18:75,21
0,755-
75,289,950   
CGTGCAGCT
CTACCGCCA
GAAC 
CCCGCTTTT
TGGTGGAGG
GGAC 
EPPK1 
chr8:143,85
7,324-
143,878,46
4 
  
CTGCGTGAT
GCCACCATG
GAGG 
TCCTGCAGC
GTCTTAGTG
CCCT 
ACSL6 
chr5:131,80
6,990-
132,012,24
3 
  
CCACACCCC
AGGAGCAAA
GATA 
GCAGTCGCA
GTATCCTCA
GGAT 
FBXO
8 
chr4:174,23
6,658-
174,284,26
4 
  
TTTTTCCCC
ACTCACTGG
AGCA 
GCCACCTGC
CACAAAGTA
CAC 
SLC2A
11 
chr22:23,85
6,703-
23,886,309   
GAGGCCAG
AGTTTGAAA
CCAGC 
CATGTACCA
CCACACCCA
GCTA 
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Table S2, related to Figure 2. Summary of clones generated by CRISPR-Cas9 
editing. 
 
Parental sgRNA 
GABPB1L 
copy 
number 
Clone # GABPB1L allele 1 
GABPB1L 
allele 2 
GBM1 GABPB1L-1 2 1 Puro cassette insertion 
3bp in-frame 
deletion 
GBM1 GABPB1L-2 2 2 Puro cassette insertion 
A frameshift 
insertion 
T98G GABPB1L-2 5 1 Puro cassette insertion 
3bp in-frame 
deletion + 
AA>GG 
dinucleotide 
sub 
T98G GABPB1L-2 5 2 Puro cassette insertion 
3bp in-frame 
deletion + 
A>G sub 
LN229 GABPB1L-2 3 1 Puro cassette insertion 
Puro cassette  
insertion 
LN229 GABPB1L-2 3 2 Puro cassette insertion 
1bp 
frameshift 
deletion 
HCT116 GABPB1L-2 2 1 Puro cassette insertion 
A frameshift 
insertion 
HCT116 GABPB1L-2 2 2 Puro cassette insertion 
A frameshift 
insertion 
HEK293T GABPB1L-2 3 1 Puro cassette insertion 
Puro cassette 
insertion 
HEK293T GABPB1L-2 4 2 Puro cassette insertion 
Puro cassette 
insertion 
NHAPC5 GABPB1L-2 3 1 Puro cassette insertion 
13bp 
frameshift 
deletion + 
G>T sub 
NHAPC5 GABPB1L-2 2 2 Puro cassette insertion 
4bp 
frameshift 
deletion 
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Parental sgRNA 
GABPB1L 
copy 
number 
Clone 
# 
GABPB1L 
allele 3 
GABPB1L 
allele 4 
GABPB1L 
allele 5 
GBM1 GABPB1L-1 2 1    
GBM1 GABPB1L-2 2 2    
T98G GABPB1L-2 5 1 
7bp 
frameshift 
deletion + 
A>T sub 
3bp in-
frame 
deletion 
7bp 
frameshift 
deletion + 
A>G sub 
T98G GABPB1L-2 5 2 
13bp 
frameshift 
deletion + 
G>A sub 
3bp in-
frame 
deletion 
13bp 
frameshift 
deletion 
LN229 GABPB1L-2 3 1 Wild-type   
LN229 GABPB1L-2 3 2 
5bp 
frameshift 
deletion 
  
HCT116 GABPB1L-2 2 1    
HCT116 GABPB1L-2 2 2    
HEK293T GABPB1L-2 3 1 Wild-type   
HEK293T GABPB1L-2 4 2 
7bp 
frameshift 
deletion 
3 bp-
inframe 
deletion 
 
NHAPC5 GABPB1L-2 3 1 
14bp 
frameshift 
deletion + 
TGA>GTT 
trinucleotide 
sub 
  
NHAPC5 GABPB1L-2 2 2    
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Table S3, related to Figure 2. Deletions induced by site-directed mutagenesis for 
the NanoBiT Protein-Protein Interaction assay. 
 
Deletion Deletion Forward Primer Reverse Primer 
Reference 
CAGCTCCTAAAGA
AAGAACAGGAAG
CAGAGGCCTACA
GACAGAAGT 
N/A N/A 
DEL1 
CAGCTCCTAAAGA
---AACAGGAAGCA 
GAGGCCTACAGA
CAGAAG 
GCCTCTGCTTCCT
GTTTCTTTAGGAG
CTGCTGT 
ACAGCAGCTCCT
AAAGAAACAGGA
AGCAGAGGC 
DEL2 
CAGCTCCTAAAGA
AAGAACAGGAAG
CAGAGGCCTACA
GAC---AG 
GCAGAGGCCTAC
AGACAGTTGGAA
GCTATGAC 
GTCATAGCTTCC
AACTGTCTGTAG
GCCTCTGC 
DEL3 
CAGCTCCTAAAGA
AAGAACAGGAAG
CAGTGGCCTAC---
----AG 
GTCATAGCTTCCA
ACTGTAGGCCTCT
GCTTCC 
GGAAGCAGAGG
CCTACAGTTGGA
AGCTATGAC 
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Table S4, related to Figure 3. EdgeR output for RNA-seq differential expression 
analysis – significantly dysregulated transcripts. 
 
Gene logFC logCPM p value FDR GABP 
HDC 8.049086875 1.534769377 3.77E-06 1.19E-06 TRUE 
MT1L -7.989910871 -0.09863883 2.44E-05 1.26E-06 FALSE 
NTRK2 -3.801031266 5.058510457 6.89E-06 2.54E-06 TRUE 
TMEM176A -7.828825804 0.439729758 9.22E-06 4.19E-06 TRUE 
TFPI2 -2.874635985 7.834920197 8.71E-05 8.17E-06 TRUE 
ZP4 -6.734234171 0.813997408 0.00013234 2.08E-05 TRUE 
PI15 -5.251817299 6.838739379 0.000173299 2.72E-05 FALSE 
HGF -5.780473372 6.411448335 0.000182063 4.11E-05 TRUE 
A2M -3.90727389 3.235761001 0.000191627 6.11E-05 TRUE 
CNTN4 -4.973501689 -0.134486213 0.000197853 8.29E-05 FALSE 
MUC15 -6.463653621 -1.409534524 0.000318064 8.60E-05 TRUE 
TMEM176B -6.349304655 0.512662696 0.00011121 9.35E-05 TRUE 
PAQR5 -4.491424719 1.761862136 0.000357144 9.75E-05 TRUE 
S100A8 -6.773080973 -2.084263094 0.0006697 1.29E-04 TRUE 
MTTP -4.278526143 0.639690227 0.000694093 2.25E-04 FALSE 
CXCL5 -6.837437146 3.362177431 0.00084337 5.73E-04 TRUE 
PRSS35 -3.677812557 0.831253062 0.001034112 9.17E-04 TRUE 
TACR1 -4.73275274 1.792163114 0.001269826 1.07E-03 TRUE 
VWA5A -2.738634399 3.818059734 0.001277974 1.41E-03 TRUE 
TSLP -3.797641961 3.815510008 0.001441245 1.60E-03 TRUE 
MUC5AC -5.126047524 -2.303393351 0.001500022 1.86E-03 TRUE 
CCL8 -5.717612815 -2.736059689 0.001518843 1.96E-03 FALSE 
CFTR -3.825218875 -0.600083635 0.001760891 2.20E-03 TRUE 
GPR183 -3.874628273 0.61338171 0.001785725 2.23E-03 FALSE 
SCUBE1 -3.849578634 3.312764199 0.002940318 2.32E-03 TRUE 
FILIP1L -1.848658792 5.016795205 0.003072085 3.10E-03 TRUE 
UGT1A1 -3.561228945 1.893582292 0.004333414 3.34E-03 TRUE 
MTHFD2P1 -3.561633667 -1.758630997 0.004428382 3.51E-03 FALSE 
UGT1A8 -3.518566387 1.591617307 0.004566677 3.63E-03 FALSE 
UGT1A9 -3.538689569 1.59770364 0.004577247 4.17E-03 TRUE 
UGT1A10 -3.504242342 1.700953281 0.004685119 4.18E-03 FALSE 
UGT1A5 -3.525442375 1.58501437 0.004776638 4.28E-03 FALSE 
EDNRB -2.261135408 2.865627923 0.014262394 0.004444416 FALSE 
NPBWR1 -3.977255085 -1.108536696 0.014850829 0.00445532 TRUE 
ADAMTS19 -4.734767573 0.56944742 0.015181039 0.004478805 FALSE 
OSM -4.095304118 -2.869050941 0.015328682 0.004498565 TRUE 
FERMT3 4.059645569 2.634903971 0.016129071 0.004509658 TRUE 
COMP 5.503876556 0.978430995 0.0164529 0.004594366 TRUE 
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Gene logFC logCPM p value FDR GABP 
HOXC12 -3.208929659 -0.224485887 0.016653143 0.004627978 FALSE 
TINCR -2.61118365 -0.134312744 0.017025472 0.004653365 TRUE 
CPXM2 7.197628142 -0.966334184 0.017044629 0.004821912 TRUE 
DRD2 -1.949115207 3.748832303 0.004809774 4.86E-03 TRUE 
ABCB1 -2.433482964 2.224454507 0.017065987 0.004909037 FALSE 
TRIML2 4.550835773 1.722655111 0.017336914 0.004969468 FALSE 
UGT1A4 -3.511937281 1.596721156 0.00491148 4.99E-03 FALSE 
S100A9 -3.91784833 -2.672701298 0.017457842 0.00516369 FALSE 
TP63 -3.097465443 0.319658804 0.00492949 5.23E-03 TRUE 
VNN2 -3.027144065 -0.538213922 0.018570754 0.005292244 FALSE 
UGT1A3 -3.495685058 1.589368931 0.005137623 5.33E-03 TRUE 
GFRA2 -3.354650807 -0.749213654 0.019250326 0.00544878 TRUE 
C22orf46 -1.03814487 5.076260978 0.01930086 0.005467721 TRUE 
GABRG3 7.085237061 -1.031518934 0.019352297 0.005476896 TRUE 
KCNJ10 -2.571389807 2.346726925 0.00513901 5.59E-03 TRUE 
CCDC129 -3.615719758 -1.53000084 0.019598041 0.005614059 FALSE 
ARHGAP25 -3.486817326 0.242890108 0.005234542 5.77E-03 TRUE 
UGT1A7 -3.447066763 1.640343407 0.005304868 0.005848268 FALSE 
LGI4 -3.790906923 0.761719472 0.00560607 0.006007118 TRUE 
TEK -3.015645979 1.01637584 0.00738532 0.006060308 FALSE 
ITGA9 -3.559080425 3.60719519 0.007523789 0.006083852 FALSE 
STX11 2.646991911 -0.765271846 0.021178821 0.006195461 TRUE 
UGT1A6 -3.277894992 1.648205951 0.007620153 0.006674252 TRUE 
SLFN11 -3.178072399 2.584142303 0.008305631 0.006708686 FALSE 
CARD11 7.308911168 -0.838862701 0.021942509 0.006723478 FALSE 
DKK1 1.135862979 6.399609258 0.022161744 0.006946396 TRUE 
GCSAML 6.874139498 0.522575017 0.022162054 0.006974946 FALSE 
CALB2 -2.274708124 1.739600397 0.022303459 0.007561587 TRUE 
CFAP221 -2.990164784 -2.596804459 0.02245537 0.007823833 TRUE 
ICK -1.177529362 5.897133924 0.022716856 0.007890192 TRUE 
THNSL2 -3.16747966 -0.972890533 0.023300243 0.008007116 TRUE 
COL9A1 -2.742505255 -1.714713086 0.023681437 0.008038152 TRUE 
TRPM2-AS -4.395247768 -2.10122456 0.008537099 0.008051612 FALSE 
LINC01133 5.831857229 -2.052404013 0.024068601 0.008079827 FALSE 
MPZ -2.631848196 3.451720212 0.024437679 0.008124566 TRUE 
HEPH 4.310881045 3.728269252 0.024505373 0.008259386 FALSE 
LRP5 1.04218618 5.732934467 0.024530521 0.008376253 TRUE 
HCN4 6.206765563 -1.749480676 0.008568601 0.008520386 FALSE 
CXCL8 -2.288300058 7.285245286 0.024680431 0.008756094 FALSE 
GABRA4 -3.886309225 -2.31045504 0.024697297 0.008860847 FALSE 
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Gene logFC logCPM p value FDR GABP 
MGP -1.920748301 2.375862658 0.024801536 0.008928433 FALSE 
OGN 6.692662816 -1.361769578 0.024813785 0.008988919 FALSE 
RPS6KA6 -3.760920498 -0.288239957 0.008742063 0.00900248 FALSE 
CXCR4 -3.700241393 -1.305420529 0.009008515 0.009339566 TRUE 
NPY -4.379119282 -2.092551971 0.009180153 0.009351572 TRUE 
LBH 2.105996896 4.635818061 0.025395215 0.009365974 TRUE 
SEMA3D -2.222618065 3.833299548 0.025509284 0.009493437 FALSE 
GLI2 1.393347145 4.996311567 0.025587327 0.009545176 TRUE 
TUBA3C 8.571782441 0.305583691 0.025886545 0.009702786 FALSE 
CXCL6 -5.012642468 1.653448556 0.009901244 0.009815216 FALSE 
PNOC 6.260495697 -0.073299604 0.025945077 0.009897571 TRUE 
FGF7 -2.477426869 3.972114776 0.010624697 0.009924656 FALSE 
FAM201A -3.515216991 -1.824509379 0.026263397 0.009956998 TRUE 
STC1 -2.180908534 7.999952952 0.011066431 0.010564754 TRUE 
GSTM5 -2.503638212 -2.172205278 0.02767625 0.010803378 TRUE 
RHOU -1.98871111 2.688956941 0.027822359 0.010889103 TRUE 
ICAM1 -2.019958711 4.131686188 0.028481383 0.011091675 TRUE 
CAMK2N1 1.364850862 6.223506183 0.028697019 0.011303897 TRUE 
ANO4 -3.484510206 1.666359696 0.011428259 0.011408738 FALSE 
LAMP3 -3.552223597 -1.075469772 0.011445934 0.011553314 FALSE 
RASSF6 -3.064589784 -0.776612714 0.028959196 0.011587878 TRUE 
EDIL3 -1.317223734 6.688413125 0.011531743 0.011705774 FALSE 
LGSN -3.69178738 -2.747318921 0.029043535 0.011921747 TRUE 
CCR3 -3.093616007 -1.921380037 0.029670965 0.012367675 FALSE 
LPAR3 -3.227301426 -2.701511134 0.030266733 0.013052732 FALSE 
CELF2 -2.041409873 3.80630249 0.030985932 0.013071533 TRUE 
LINC01915 -3.375066359 0.336963229 0.011647698 0.013447724 FALSE 
MMP10 -2.904323636 -1.33229792 0.031065334 0.013849581 FALSE 
C19orf81 5.604702183 -2.202590718 0.031431958 0.013868809 TRUE 
MAGEB6 3.498881725 -0.411480195 0.031494237 0.013904022 FALSE 
SHANK1 4.099124742 1.03358378 0.031765229 0.014038482 FALSE 
ADD2 3.494912278 5.038973012 0.012322207 0.014135468 TRUE 
CEMIP 1.793909161 5.140891621 0.032585671 0.014406602 TRUE 
CA8 -2.754297386 1.669390029 0.013297412 0.014572724 TRUE 
ANKRD1 3.070558745 1.945731811 0.013434979 0.014815634 TRUE 
RCSD1 -3.035952408 -1.333739678 0.013506384 0.014916236 TRUE 
RARRES2 -2.991917543 0.725467047 0.033119001 0.014958541 TRUE 
FAR2P2 -3.345728563 -1.97643088 0.033209553 0.015243021 FALSE 
KRTAP2-3 2.667296044 0.124150413 0.033413427 0.0156409 FALSE 
CP 3.321487346 3.428477829 0.033423621 0.015735756 TRUE 
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Gene logFC logCPM p value FDR GABP 
TMEM100 -2.033055064 4.333255512 0.033511783 0.017176861 TRUE 
EPHB6 4.240470791 0.070251498 0.033641561 0.017564371 FALSE 
ADAMTS2 2.380152602 4.706452222 0.034311407 0.017650344 TRUE 
IL32 2.274203801 2.225854337 0.034977936 0.017810539 FALSE 
TERT -1.750307861 0.213014433 0.035226626 0.017823031 TRUE 
VNN1 -2.756717353 -0.088878982 0.03586095 0.018046593 FALSE 
PIEZO2 -2.256951639 5.926920198 0.035915145 0.018708996 TRUE 
FST -1.330299012 4.259125321 0.036245576 0.019504434 FALSE 
MMP13 -3.40515214 4.267422058 0.036613208 0.020313136 FALSE 
CUZD1 3.371428711 -0.134743191 0.036793542 0.02035303 FALSE 
SYTL2 -1.245575095 6.001499744 0.03706273 0.02088963 TRUE 
MAGEA10 6.028351547 -0.258151211 0.037168142 0.021329389 FALSE 
DCT -2.565663132 -1.442067073 0.037819313 0.021565603 TRUE 
CPA6 -2.620437648 -0.545367347 0.037839646 0.021955062 FALSE 
ZNF853 -2.231638703 2.135426603 0.037874743 0.022444453 TRUE 
OBSCN 1.669276202 4.645274953 0.03794602 0.023967613 TRUE 
SOD3 -3.352493857 4.218582864 0.038036124 0.024124595 FALSE 
NTF3 3.721204024 1.922630691 0.038242526 0.024377605 TRUE 
ITIH6 -3.957590458 0.909436366 0.038347785 0.025953053 FALSE 
RASGRP3 -1.636705793 4.04621766 0.038583385 0.026088634 FALSE 
ZDHHC15 -2.414043718 -1.293863375 0.038633607 0.026574069 FALSE 
SLC27A2 7.048488564 -1.099868085 0.039556893 0.027863375 FALSE 
GABPB1 0.958566168 5.287148867 0.040974398 0.028450711 TRUE 
PRG4 5.131122265 1.44118635 0.041760287 0.028461106 FALSE 
INPP4B 1.156260342 4.794478797 0.042015845 0.028539707 TRUE 
TRBC2 6.319154779 0.764636991 0.0428078 0.028948732 FALSE 
PTPRO 3.093470433 0.042944827 0.043106557 0.029129824 FALSE 
DHRS2 2.458361885 3.316124571 0.043208714 0.029242938 TRUE 
PCDH17 -1.867341817 1.770862128 0.043232785 0.029407116 FALSE 
FRK -1.763423284 2.147253479 0.043593579 0.029459898 TRUE 
GNAI1 -1.00740864 5.872330238 0.044810868 0.029862901 TRUE 
PCOLCE 0.99487556 7.685532591 0.045121619 0.030036488 TRUE 
CD1D 4.303185934 0.402900161 0.045846003 0.03181145 FALSE 
OLMALINC -1.722715746 2.635640775 0.046590009 0.032586978 FALSE 
ARHGEF35 -2.67250947 -0.847504702 0.04681797 0.033781237 FALSE 
AKR1B1 -1.050628598 8.161878847 0.047029972 0.03402702 FALSE 
IL1B -2.434407874 4.330995301 0.047723229 0.035596027 TRUE 
PTGS2 -1.832849526 4.098331802 0.048697998 0.03585096 TRUE 
DEFB124 -3.375675068 -1.280762949 0.048851133 0.041407851 FALSE 
TF -2.284190047 3.960297857 0.049367378 0.04703088 TRUE 
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Table S5, related to Figure 3. GO-enrichment for genes differentially expressed 
between control and GABPβ1L-reduced TERT promoter mutant lines. 
 
Process GOTerm Accession 
Gene 
Determinants FDR 
Glucuronidation 
0052697 
UGT1A10, 
UGT1A8, UGT1A1, 
UGT1A4, UGT1A5, 
UGT1A3, UGT1A9 
1.44E-11 
1904223 
1904224 
2001030 
2001029 
0052696 
0052695 
0006063 
0019585 
Cellular 
development 
0044707 
HOXC12, RHOU, 
FST, COL9A1, 
TMEM176B, 
SHANK1, UGT1A1, 
LRP5, EDIL3, 
CXCR4, NTF3, 
NPY, OGN, DKK1, 
GPR183, 
ZDHHC15, LGI4, 
RPS6KA6, ICK, 
FRK, MGP, LPAR3, 
ADAMTS2, 
KCNJ10, FERMT3, 
SP7, TERT, 
S100A9, VNN1, 
NTRK2, GABRA4, 
STC1, S100A8, 
PCOLCE, CD1D, 
PTGS2, KCNA1, 
ANKRD1, HGF 
3.0903E-08 
0044767 
0032502 
0044763 
0048856 
0048869 
007275 
Cell-to-cell 
signaling 
0007267 
STX11, DKK1, 
LPAR3, TACR1, 
HCN4, KCNJ10, 
NPBWR1, 
SHANK1, TERT, 
S100A9, NTRK2, 
CXCL5, GABRA4, 
LRP5, CCL8, 
PTGS2, KCNA1, 
NTF3, NPY, HGF 
8.26038E-08 0099536 
0099537 
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Process GoTerm Accession 
Gene 
Determinants FDR 
Fatty acid 
metabolism 
0045922 UGT1A10, 
UGT1A8, UGT1A1, 
UGT1A4, UGT1A3, 
UGT1A9 
8.31764E-07 0019217 
0045833 
Cell differentiation 0030154 
DKK1, FST, 
GPR183, LGI4, 
FRK, MGP, 
COL9A1, LPAR3, 
TMEM176B, 
KCNJ10, FERMT3, 
SP7, SHANK1, 
VNN1, S100A9, 
NTRK2, STC1, 
LRP5, CXCR4, 
S100A8, CD1D, 
PTGS2, KCNA1, 
NTF3, NPY, OGN, 
HGF, ANKRD1 
2.58226E-07 
Cell proliferation 0008283 
GPR183, LGI4, 
FRK, TACR1, 
ABCB1, ZP4, 
TERT, NTRK2, 
CXCL5, STC1, 
LRP5, CCL8, 
CD1D, PTGS2, 
KCNA1, NPY, 
NTF3, HGF, OGN 
8.29851E-06 
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CHAPTER 3: DISRUPTION OF GABPβ1L FUNCTION IS SUFFICIENT TO REVERSE 
GLIOBLASTOMA REPLICATIVE IMMORTALITY IN A TERT PROMOTER 
MUTATION-DEPENDENT MANNER 
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3.1 ABSTRACT 
 The ETS family transcription factor GABP binds to and activates the mutant TERT 
promoter as a GABPβ1L-containing GABP tetramer in glioblastoma. Using CRISPR-
Cas9-mediated disruption of GABPβ1L function in glioblastoma, we have identified 
GABPβ1L as necessary for cellular immortality in a TERT promoter mutation-dependent 
manner. Reduction in GABPβ1L function was sufficient to induce telomere shortening 
and loss of cellular viability exclusively in TERT promoter mutant glioblastoma lines in 
vitro. Expression of exogenous GABPβ1L or TERT was sufficient to fully and 
immediately rescue both telomere shortening and cell death phenotypes. Additionally, 
orthotopic xenografting of GABPβ1L-reduced, TERT promoter mutant glioblastoma cells 
rendered lower tumor burden and longer overall survival in mice. These results highlight 
the critical role of GABPβ1L in enabling immortality in TERT promoter mutant 
glioblastoma. 
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3.2 GABPβ1L-MEDIATED ACTIVATION OF THE MUTANT TERT PROMOTER IS 
REQUIRED FOR TELOMERE MAINTENANCE IN GBM 
As TERT expression is closely linked to telomere maintenance, we next 
investigated the effects of reducing GABPβ1L function on telomere length in the TERT 
promoter mutant cell lines. Measurements of mean telomere length at four time points 
following editing uncovered significant telomere loss only in clones from TERT promoter 
mutant cells with reduced GABPβ1L function (Figure 4A). Expression of exogenous 
GABPβ1L or TERT was sufficient to halt this telomere loss in all clones (Figure 4B). 
Telomere shortening and uncapping can result in end-to-end fusions of telomere-
deficient chromosomes and the formation of chromatin bridges (Capper et al., 2007; 
der-Sarkissian et al., 2004; Hackett et al., 2001). We identified chromatin bridges in a 
significant proportion of the TERT promoter mutant, but not TERT promoter wild-type, 
GABPβ1L-reduced clones 70-75 days after editing, indicating widespread telomere 
dysfunction following telomere loss (Figures 4C and S4A). Telomere dysfunction was 
readily rescued by expression of exogenous GABPβ1L or TERT (Figures S4B and 
S4C). These data support that disrupting GABPβ1L function is sufficient to induce 
telomere loss and dysfunction in a TERT promoter mutation-dependent manner. 
 
3.3 DISRUPTING GABPβ1L FUNCTION IS SUFFICIENT TO INDUCE SHORT-TERM 
AND LONG-TERM GROWTH DEFECTS IN TERT PROMOTER MUTANT LINES IN 
VITRO 
 Previous studies have reported that TERT depletion and telomere dysfunction 
result in both immediate and long-term growth defects (Cao et al., 2002; Fitzgerald et 
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al., 1999; Iwado et al., 2007; Shay and Wright, 2006). Thus we sought to determine 
whether reduction of GABPβ1L results in a growth phenotype as a result of reduced 
expression from the mutant TERT promoter. Monitoring cell growth prior to significant 
telomere loss (days 45-48 post-editing) revealed a growth defect in all TERT promoter-
mutant GABPβ1L-reduced clones (Figure S5A). We further inhibited β1L in the β1L-
reduced lines with an LNA-ASO to deplete any residual β1L function and observed no 
further changes in cell growth (Figure S5B) or TERT expression (Figure S5C) 
regardless of TERT promoter status. Interestingly, LNA-ASO-mediated knockdown of 
GABPβ1L in TERT promoter mutant control lines significantly reduced cell growth 
compared to the LNA-ASO controls, suggesting a short-term growth effect following 
reduction of GABPβ1L and TERT levels. 
 Long-term changes in growth and cell viability may occur due to telomere 
dysfunction in the TERT promoter mutant, GABPβ1L-reduced clones. We monitored 
each GABPβ1L-reduced line throughout the process of telomere loss and identified a 
progressive loss of cell viability in GABPβ1L-reduced clones from TERT promoter 
mutant cells, a phenotype that was absent in the clones from TERT promoter wild-type 
cells (Figure 5A). We observed complete growth arrest in both GBM1 GABPβ1L-
reduced clones, and substantial but incomplete arrest of the cultures of T98G and 
LN229 clones. GABPβ1L-reduced clones derived from T98G underwent complete 
growth arrest in all cases except one instance when a surviving population emerged 
following long-term culture. Unlike GBM1 and T98G cells, both LN229 clones 
consistently had a population of viable cells emerge following the period of massive cell 
death. The underlying cause of this heterogeneity in cellular response among the three 
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lines is unknown, but could reflect residual function of GABPβ1L in GABPβ1L-reduced 
clones, potential GABPβ1L-independent mechanisms of activation of the mutant TERT 
promoter, or other factors. Importantly, overexpression of either exogenous GABPβ1L 
or TERT was sufficient to counteract the loss of viability (Figure 5B). This gradual loss 
of viability signified the loss of replicative immortality in TERT promoter mutant 
GABPβ1L-reduced clones. 
 
3.4 GABPβ1L-REDUCED GBM LINES ACCRUE DNA DAMAGE AND UNDERGO 
MITOTIC CELL DEATH IN A TERT PROMOTER MUTATION-DEPENDENT MANNER 	 The direct correlation between telomere shortening and viability loss (Figure 
S6A) suggested that the loss of viability is a consequence of cell death or senescence 
induced by telomere dysfunction. The formation of chromatin bridges after telomere 
dysfunction induces breakage-fusion-bridge cycles that lead to the accrual of significant 
DNA damage in telomere-deficient cells (der-Sarkissian et al., 2004; Hackett et al., 
2001). While canonical apoptosis and cellular senescence have been widely observed 
as results of significant DNA damage after telomere dysfunction, both mechanisms are 
dependent on functional p53 and RB pathways (Saretzki et al., 1999; Whitaker et al., 
1995). However, these two pathways are commonly mutated in TERT promoter mutant 
GBM, including the GBM1, T98G, and LN229 lines (Table S6), making apoptosis and 
senescence unlikely to occur at high levels. In p53- and RB-deficient cells, mitotic cell 
death has been implicated as a primary phenotype following telomere dysfunction 
(Fragkos and Beard, 2011; Hayashi et al., 2015). Mitotic cell death can result from 
chromosome fusions, high-level chromosomal rearrangements and DNA damage, oft-
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described consequences of breakage-fusion-bridge cycles during telomere dysfunction 
(Hayashi et al., 2015; Vakifahmetoglu et al., 2008; Vitale et al., 2011).	
 Indeed, we observed a significant increase in the amount of the DNA damage 
marker γ-H2AX exclusive to the GABPβ1L-reduced clones from TERT promoter mutant 
cells by day 73 post- editing (Figures 6A and S6B). Likewise, we identified giant cell 
micronucleation, a prominent feature of mitotic cell death (Ianzini and Mackey, 1997; 
Vakifahmetoglu et al., 2008), in GABPβ1L-reduced, TERT promoter mutant – but not 
wild-type – cells at this same time point (Figures 6B and S6C). Overexpression of 
exogenous GABPβ1L or TERT was sufficient to fully rescue both the DNA damage 
(Figure S7A) and mitotic cell death phenotypes (Figure S7B). Additionally, chromatin 
bridge formation, γ-H2AX staining, and giant cell micronucleation accumulated over 
three time points (days 45, 61, and 73 post-editing) in the LN229 β1L-reduced clones, 
thus supporting that these phenotypes may be dependent on telomere shortening 
(Figure S7C). 
 Moreover, cell cycle analysis of the GABPβ1L-reduced TERT promoter mutant 
cells between day 70 and day 80 post-CRISPR-Cas9 editing revealed a modest G2/M 
enrichment, another hallmark of cells undergoing mitotic cell death (Deeraksa et al., 
2013) (Figures 6C and 6D). Cytometric analysis of senescence and apoptosis/necrosis 
markers identified a modest increase in apoptosis in TERT promoter mutant GABPβ1L-
reduced clones, thereby implicating non-apoptotic mitotic cell death, with modest 
contributions from canonical apoptosis, as the primary driver of cell death in these lines 
(Figure S7D). Therefore, TERT promoter mutation-dependent telomere dysfunction 
induced by reducing the function of the GABP tetramer-forming isoform GABPβ1L and 
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reducing TERT expression culminates in a loss of replicative immortality characterized 
by a profound loss of cell viability primarily driven by a mitotic cell death mechanism. 
 
3.5 REDUCING GABPβ1L FUNCTION IMPAIRS TUMOR GROWTH AND EXTENDS 
MOUSE SURVIVAL IN VIVO 
In order to determine the effects of GABPβ1L disruption in a TERT promoter 
mutant setting in vivo, we orthotopically injected CRISPR control or GABPβ1L-reduced 
LN229 cells expressing luciferase into nude mice and monitored tumor engraftment and 
growth via bioluminescence imaging (BLI). A proportion of the mice injected with 
GABPβ1L-reduced tumor cells did not show evidence of tumor formation over the time 
course, and those that did form tumors showed significantly decreased tumor growth 
when compared to mice injected with control cells (Figures 7A and 7B). Importantly, 
mice injected with the control lines had a significantly shorter median survival compared 
to mice bearing the β1L-reduced lines (Figure 7C). Despite LN229 C1 and C2 having an 
attenuated growth arrest phenotype compared to the other lines (Figure 5A), GABPβ1L 
disruption and reduced TERT expression in these lines were sufficient to significantly 
inhibit tumor formation and growth and extend survival in mice injected with them. 
Furthermore, lentiviral transduction of LN229 C1 and C2 with a TERT expression vector 
was sufficient to rescue both the tumor growth and survival phenotypes (Figures 7D-F). 
In conclusion, inhibition of the mutant TERT promoter through disrupting GABPβ1L 
function is sufficient to prolong survival in mice bearing GBM xenografts. 
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3.6 MAIN FIGURES
 
Figure 4. GABPβ1L-mediated activation of the mutant TERT promoter is required 
for telomere maintenance in GBM.  
(A) Telomere length at days 44, 61, and 78 in TERT promoter mutant lines or days 44, 
61 and 83 in TERT promoter wild-type lines post-editing relative to day 33 post-editing 
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for CTRL or GABPβ1L-reduced clones. *p value<0.05, two-sided Student’s t-test 
comparing values between CTRL and GABPβ1L-reduced clones at day 78/83 for each 
respective line. Values are mean ± S.D. of at least three independent assays.  
(B) Relative telomere length after transfection of an empty (VECTOR), GABPβ1L, or 
TERT expression vector in TERT promoter-mutant lines 78 or 83 days post-editing. Red 
dotted line indicates time of transfection (at day 58 [LN229] or 61 [GBM1 and T98G] 
post-editing). *p value<0.05, two-sided Student’s t-test of values of GABPβ1L or TERT 
versus VECTOR at day 78/83. Values are mean ± S.D. of at least three independent 
experiments.  
(C) Representative DAPI images (left images) and quantification (right graphs) of 
chromatin bridges (arrow) in CTRL or GABPβ1L-reduced clones at days 70-75 post-
editing. Scale bar = 20 µm. *p value<0.05, **p value<0.01, two-sided Student’s t-test 
compared to CTRL. Quantification values are weighted mean ± S.D. of at least ten 
independent fields of view.  
See also Figure S4. 
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Figure 5. GABPβ1L reduction induces loss of replicative immortality in TERT 
promoter-mutant GBM lines.  
(A) Cell viability of CTRL or GABPβ1L-reduced clones measured approximately every 7 
days from day 33 to day 99 post-editing for TERT promoter mutant and wild-type lines. 
**p value<0.01, Welch’s t-test of CTRL clones versus GABPβ1L-reduced clones at day 
83 post-editing.  
(B) Cell viability measurements following transfection with an empty (VECTOR), 
GABPβ1L, or TERT expression vector. Red dotted line indicates time of transfection. *p 
value<0.05, **p value<0.01, Welch’s t-test of vector transfected cells versus GABPβ1L 
and TERT transfected cells at the final recorded time-point for each line.  
Values are median of three independent experiments.  
See also Figure S5. 
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Figure 6. GABPβ1L-reduced GBM lines accrue DNA damage and undergo mitotic 
cell death in a TERT promoter mutation-dependent manner.  
(A) Representative images (left images) and quantification (right graphs) of γ-H2AX 
staining in CTRL or GABPβ1L-reduced clones at day 70-75 post-editing. Scale bar = 
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20µm. **p value<0.01, two-sided Student’s t-test compared to CTRL. Quantification 
values are sums of at least ten independent fields of view.  
(B) Representative DAPI images (left images) and quantification (right graphs) of giant 
cell micronucleation (GCM) in CTRL or GABPβ1L-reduced clones at day 70-75 post-
editing. Scale bar = 20 µm. *p value<0.05, **p value<0.01, two-sided Student’s t-test 
compared to CTRL. Quantification values are weighted mean ± S.D. of at least ten 
independent fields of view.  
(C,D) Histograms (C) and quantification (D) for cell cycle analysis of CTRL or 
GABPβ1L-reduced LN229 (top graphs) and NHAPC5 (bottom graphs) lines at day 75 
post-editing.  
See also Figures S6-S7 and Table S6. 
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Figure 7. Reduction of GABPβ1L impairs tumor growth and extends mouse 
survival in vivo.  
(A) Representative IVIS bioluminescent images of CTRL or GABPβ1L-reduced LN229-
derived tumors at 7 time points post-intracranial injection (injected on cellular day 51 
post-editing). DPI = days post-injection.  
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(B) Relative tumor bioluminescence quantified twice per week for each group (CTRL: 
n=12, C1: n=12, C2: n=10) until first recorded mortality. **p value<0.01, two-sided 
Student’s t-test compared to CTRL peak luminescence. Values are mean ± S.D of all 
mice in each group.  
(C) Kaplan-Meier survival curve displaying disease-specific survival of mice (Simonsen 
Labs) injected with LN229 CTRL or C1 and C2 GABPβ1L-reduced cells over time. **p 
value<0.01, log-rank test compared to CTRL.  
(D) TERT expression 4 days post-transduction of CTRL or GABPβ1L-reduced LN229 
clones (41 days post-editing) with either a control (V) or TERT (T) lentiviral expression 
vector. **p value<0.01, two-sided Student’s t-test relative to respective vector (V) 
control. Values are mean ± S.D of three independent experiments.  
(E) Relative tumor bioluminescence quantified twice per week for each group (n=7 mice 
per group) following stable transduction with a control (V) or TERT (T) lentiviral 
expression vector. **p value<0.01, two-sided Student’s t-test compared to vector control 
peak luminescence for each respective line. Values are mean ± S.D of all mice in each 
group.  
(F) Kaplan-Meier survival curve displaying disease-specific survival of mice (Envigo) 
injected with LN229 CTRL or C1 and C2 GABPβ1L-reduced cells following stable 
transduction with a control (V) or TERT (T) lentiviral expression vector. **p value<0.01, 
log-rank test compared to CTRL. 
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3.7 SUPPLEMENTAL FIGURES 
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Figure S4, related to Figure 4. Expression of exogenous GABPβ1L or TERT is 
sufficient to rescue telomere dysfunction in GABPβ1L-reduced LN229 lines.  
(A) Representative DAPI images (left images) and quantification (right graphs) of 
chromatin bridges in CTRL or GABPβ1L-reduced clones derived from HCT116 or 
HEK293T TERT promoter wild-type lines. Scale bar = 20 µm. N.D. = Not detected. 
Quantification values are weighted mean ± S.D. of at least ten independent fields of 
view.  
(B) Representative DAPI images (left images) and quantification (right graphs) of 
chromatin bridges in GABPβ1L-reduced LN229 clones transfected with a CONTROL, 
GABPβ1L, or TERT expression vector. Scale bar = 20 µm. *p value<0.05, **p 
value<0.01, two-sided Student’s t-test relative to CONTROL. Quantification values are 
weighted mean ± S.D. of at least ten independent fields of view.  
(C) TERT expression measured by RT-qPCR 7 days post-transfection of GABPβ1L-
reduced LN229 clones (58 days post-editing) with either a CONTROL or TERT 
expression vector. **p value<0.01, two-sided Student’s t-test relative to CONTROL. 
Values are mean ± S.D. of three independent experiments. 
 
	 54 
 
Figure S5, related to Figure 5. GABPβ1L reduction induces growth defects in 
TERT promoter mutant lines.  
(A) Percent growth of TERT promoter mutant (top graphs) and wild-type (bottom 
graphs) CRISPR control (CTRL) or GABPβ1L-reduced clones (C1 and C2) relative to 
the initial time point. *p value<0.05, **p value<0.01, two-sided Student’s t-test compared 
to CTRL (final time point).  
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(B) Percent growth of TERT promoter mutant (top graphs) and wild-type (bottom 
graphs) CRISPR control (CTRL) or GABPβ1L-reduced clones (C1 and C2) relative to 
the initial time point following transfection with a scrambled control (LNA-CTRL) or 
GABPB1L-targeting (LNA-GABPB1L) LNA-ASO. Growth was measured 0, 48, and 96 
hr post-transfection. *p value<0.05, **p value<0.01, two-sided Student’s t-test compared 
to a control LNA-ASO (LNA-CTRL) at the final time point for each clone (CTRL or 
GABPβ1L-reduced).  
(C) Relative TERT expression of GABPβ1L-reduced clones following transfection with a 
scrambled control (LNA-CTRL) or GABPB1L-targeting (LNA-GABPB1L) LNA-ASO.  
All values are mean ± S.D. of three independent experiments. 
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Figure S6, related to Figure 6. GABPβ1L reduction does not induce DNA damage 
and mitotic cell death in TERT promoter wild-type cell lines.  
(A) Correlation of relative telomere length and cellular viability across GABPβ1L-
reduced clones from all TERT promoter-mutant cell lines (GBM1, T98G, and LN229). 
Spearman rho=-0.90, p value<0.001.  
(B) Representative images (left images) and quantification (right graphs) of γ-H2AX 
staining in CTRL or GABPβ1L-reduced HCT116 and HEK293T clones. Scale bar = 20 
µm. n.s. = not significant, two-sided Student’s t-test compared to CTRL. Quantification 
values are sums of at least ten independent fields of view.  
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(C) Representative DAPI images (left images) and quantification (right graphs) of giant 
cell micronucleation (GCM) in CTRL or GABPβ1L-reduced HCT116 and HEK293T 
clones. Scale bar = 20 µm. N.D = Not detected. Quantification values are weighted 
mean ± S.D. of at least ten independent fields of view. 
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Figure S7, related to Figure 6. Expression of exogenous GABPβ1L or TERT is 
sufficient to rescue DNA damage and mitotic cell death in GABPβ1L-reduced 
LN229 clones.  
(A) Representative images (left images) and quantification (right graphs) of γ-H2AX 
staining in GABPβ1L-reduced LN229 clones transfected with a CONTROL, GABPβ1L, 
or TERT expression vector at 73 days post-editing. Scale bar = 20 µm. *p value<0.05, 
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**p value<0.01, Student’s t-test relative to CONTROL. Quantification values are sums of 
at least ten independent fields of view.  
(B) Representative DAPI images (left images) and quantification (right graphs) of giant 
cell micronucleation (GCM) in GABPβ1L-reduced LN229 clones transfected with a 
CONTROL, GABPβ1L, or TERT expression vector at 73 days post-editing. Scale bar = 
20 µm. *p value<0.05, Student’s t-test relative to CONTROL. Quantification values are 
weighted mean ± S.D. of at least ten independent fields of view.  
(C) Quantification of chromatin bridge formation, γ-H2AX staining (% positive cells), and 
giant cell micronucleation (GCM) in LN229 CTRL and GABPβ1L-reduced lines at days 
45, 61, and 73 post-editing. Values are mean of at least five independent fields of view.  
(D) Dot plots quantifying expression of the apoptosis/necrosis marker annexin-V (PE; x-
axis) and the senescence marker SA-β-Gal (C-12FDG [FITC]; y-axis) as determined by 
flow cytometry at day 75 post-editing.  
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3.8 SUPPLEMENTAL TABLES 
 
Table S6, related to Figure 6. Descriptions for cell lines used for CRISPR-Cas9 
editing, including p53 and RB pathway status and alterations. 
 
 
Cell line ATCC No. Description TERT promoter mutation? 
GBM1 N/A 
Human patient-
derived primary 
GBM culture 
C228T 
T98G CRL-1690 Human primary GBM line C250T 
LN229 CRL-2611 Human primary GBM line C228T 
HCT116 CCL-247 Human colon cancer line No 
HEK293T CRL-3216 Human embryonic kidney line No 
NHAPC5 N/A 
Normal human 
astrocyte line; stably 
expressing E6 and 
E7 viral proteins 
and mtIDH (R132H 
variant); selected 
post-crisis and 
expressing TERT 
from the 
endogenous TERT 
promoter (Ohba et 
al. 2016) 
No 
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Cell line Active RB pathway? 
RB pathway 
alteration 
Active p53 
pathway? 
p53 pathway 
alteration 
GBM1 No 
CDKN2A 
homozygous 
deletion 
No 
TP53 p.C141F 
homozygous 
mutation 
T98G No 
CDKN2A 
homozygous 
deletion 
No 
TP53 p.M237I 
homozygous 
mutation 
LN229 No 
CDKN2A 
homozygous 
deletion 
No 
TP53 p.P98L 
mutation with 
LOH 
HCT116 No 
CDKN2A 
p.R24fs*20  
homozygous 
mutation 
Yes 
High MDM4 
expression 
(Mancini et al. 
2009) 
HEK293T Yes N/A Yes N/A 
NHAPC5 No E7 protein expression No 
E6 protein 
expression 
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CHAPTER 4: MATERIALS AND METHODS 
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4.1 EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Cell lines and primary cell cultures 
GBM1 (male), T98G (male), LN229 (female), and LN18 (male) cells were cultured in 
DMEM/Ham’s F-12 1:1 media, 10% FBS, 1% Penicillin/Streptomycin. The GBM1 
primary culture was previously described in Bell et al. 2015 (Bell et al., 2015). HEK293T 
(female) and NHAPC5 (male) cells were cultured in DMEM H-21 media, supplemented 
with 10% FBS, 1% Non- Essential Amino Acids, 1% Glutamine and 1% 
Penicillin/Streptomycin. The NHAPC5 culture was previously described in Ohba et al. 
2016 (Ohba et al., 2016). HCT116 cells (male) were cultured in McCoy’s 5A media 
supplemented with 10% FBS and 1% Penicillin/Streptomycin. 
 
SF7996 (male; passage 6), SF8249 (male; passage 4), SF8279 (male; passage 4), 
SF9030 (male; passage 3), and SF11411 (female; passage 4) are TERT promoter-
mutant, IDH1-wild-type patient-derived early passage glioma neurosphere (GNS) GBM 
cultures and were previous described in Fouse et al. 2014 (Fouse et al., 2014). SF7996 
(GNS) and GBM1 (serum) are derived from the same piece of tumor tissue from one 
patient and differ only in derivation conditions. SF10417 (male; passage 9) is a TERT 
promoter-mutant, IDH1-mutant patient-derived early passage recurrent high-grade GNS 
oligodendroglioma culture. hNPCs (male) are human Neural Precursor Cells derived 
from human induced pluripotent stem cells as previous described (Xu et al., 2016). All 
GNS cells and hNPCs were cultured in Neurocult NS-A (Stem Cell Technologies) 
supplemented with 2 mM L-Glutamine, 1% Penicillin/Streptomycin, B-27 without vitamin 
A (Invitrogen), N2 supplement, 20 ng/mL EGF, and 20 ng/mL bFGF, and 1% sodium 
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pyruvate. SF10417 was additionally supplemented with 20 ng/mL PDGF-AA. hNPCs 
were additionally supplemented with 5 ng/mL heparin. Cells were grown on 1.6 ug/cm2 
laminin-coated flasks and dissociated with StemPro Accutase (Gibco). All cells were 
maintained at 37º Celsius, 5% CO2. LN229, T98G, HEK293T, LN18 and HCT116 were 
acquired from ATCC through the UCSF Cell Culture Facility and validated for cell 
identity via STR testing. The GBM1, SF7996, SF8249, SF8279, SF9030, SF11411, and 
SF10417 cells are patient-derived cultures validated to be tumor by exome-seq and/or 
RNA-seq. hNPCs (Xu et al., 2016) were a generous gift from Haoqian Xu and Michael 
Oldham at University of California, San Francisco. All cells tested negative for 
mycoplasma contamination. 
 
Animals 
Mice and Animal Housing 
Athymic (nu/nu) female mice at 5 weeks of age were purchased from Simonson 
Laboratories (Figures 7A-C) and Harlan Laboratories (Figures 7D and E). Five mice 
were grouped per cage. Humane endpoints for sacrifice were established as >15% 
body weight loss from last weighing and/or the presence of gross neurological 
symptoms such as hunching, asocial behavior, or spastic behavior. All protocols 
regarding animal studies were approved by the UCSF Institutional Animal Care and Use 
Committee (IACUC; protocol AN111064-03B) for Dr. Theodore Nicolaides at the 
University of California, San Francisco. 
 
 
	 65 
Orthotopic xenografting and in vivo imaging 
144 hr prior to orthotopic xenografting, LN229 control and GABPβ1L-reduced lines were 
stably transduced with Firefly Luciferase Lentifect™ Purified Lentiviral Particles catalog 
# LPP-FLUC-Lv105 (Genecopoiea) with MOI=5. Separately, 240 hr prior to orthotopic 
xenografting, LN229 control and β1L-reduced lines were stably transduced with either 
EF1a-TERT-RFP-Bsd catalog # LV1131-RB (GenTarget) or EF1a-empty-RFP-Bsd 
catalog # LVP-427 lentiviral particles with MOI=0.5. Transduced cells were selected in 5 
µg/mL blasticidin (Sigma-Aldrich) for 72 hr, validated for TERT and RFP expression via 
RT-qPCR and fluorescent imaging, respectively, and stably transduced with Firefly 
Luciferase Lentifect™ Purified Lentiviral Particles catalog # LPP-FLUC-Lv105 
(Genecopoiea) with MOI=5. All cells were verified for stable luciferase expression prior 
to injection. 30,000 LN229 CRISPR control or β1L-reduced cells 51 days post-editing 
per mouse (CTRL=12 mice; C1=12 mice; C2=10 mice) or 50,000 LN229 stably 
transduced TERT (T) or empty vector (V) CRISPR control or GABPβ1L-reduced cells (7 
mice per group) were injected into the frontal cortex. Animal’s body weight was 
measured 3 times per week, tumor size via bioluminescent imaging (BLI) on a Xenogen 
IVIS Spectrum Imaging System was evaluated 2 times per week, and general behavior 
and symptomatology was evaluated daily. All BLI images were taken with small binning 
and a normalized exposure of 30 s recorded 12 min after intraperitoneal injection of 5 
µL/g of 30 mg/mL D-Luciferin catalog # LUCK-100 (GoldBio). 
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4.2 METHOD DETAILS 
TCGA expression data set 
The collection of the data from The Cancer Genome Atlas (TCGA) (Cancer Genome 
Atlas Research, 2008) was compliant with all applicable laws, regulations, and policies 
for the protection of human subjects, and necessary ethical approvals were obtained. 
Analysis of all data analysis was done in R project version 3.3.2 (http://www.r-
project.org/). RSEM normalized RNA-seq expression data for GABP isoforms (GABPA: 
uc002yly; GABPB1S: uc001zyc, uc001zyd, uc001zye, uc001zyf; GABPB1L: uc001zya, 
uc001zyb; GABPB2: uc001ewr, uc001ews, uc001ewt) and TERT were downloaded 
along with clinical information from TCGA (level 3 normalized data, December 2015, 
http://tcga-data.nci.nih.gov/tcga/dataAccessMatrix.htm) for 143 GBM (109 TERT-
expressing and 34 TERT- non-expressing) samples, 49 oligodendroglioma (49 TERT 
promoter-mutant samples), and 249 colorectal cancer (249 TERT-expressing) samples. 
TERT mutation status was obtained, when available, from Ceccarelli et al for the glioma 
samples (Ceccarelli et al., 2016). GABP isoforms were analyzed for monotonic 
associations with TERT using Spearman’s correlation. H0: Spearman’s Rho=0; H1: 
Spearman Rho≠0; α=0.05. A linear trend-line was generated using the PCA orthogonal 
regression line. 
 
Transcriptome sequencing and analysis 
Total cellular RNA was isolated from GBM1, T98G, and LN229 CRISPR control and 
GABPβ1L-reduced clones 45 days post-editing via standard TRIzol protocol 
(ThermoFisher). Prior to library synthesis, RNA was treated with DNase (Roche), 
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scored on an Agilent 2100 Bioanalyzer for quality control, and quantified on a Qubit® 
Fluoremeter using the Qubit RNA HS Assay kit (ThermoFisher). Only the samples with 
RIN >7 were used for RNA-seq. RNA-seq libraries were prepared with the KAPA 
Stranded mRNA-Seq kit for Illumina platforms (KAPA Biosystems) according to 
manufacturer’s instructions. Briefly, 1 µg RNA was used for mRNA capture. After 
fragmentation, first strand synthesis, second strand synthesis, and A-tailing, Illumina 
adaptors with dual indexes were ligated. The libraries were amplified 11 cycles before 
pooling with 8-10 samples/lane for sequencing. All libraries were sequenced at the 
UCSF Center for Advanced Technology on an Illumina HiSeq4000 sequencer with 
paired-end reads and an average read length of 50 base pairs. 
Adapter and polyA sequences were removed from reads using cutadapt v1.8.1, with the 
minimum overlap between adapter and the 3′ of the read set to 1 nt. Reads shorter than 
20 nts after adapter trimming were discarded. Reads were aligned with TopHat 
(v2.0.14) using a GENCODE V19 transcriptome-guided alignment with parameters –r 
200 –library-type fr-firststrand, --prefilter-multihits genome. To estimate transcript 
abundance, aligned data was processed with FeatureCounts (v1.4.6) with parameters -
s 2 -B -p -O -T 24 using a GENCODE V19 GTF reference. 
EdgeR was used to determine differential expression between the six GABPβ1L-
reduced clones and three CRISPR control clones from TERT promoter mutant lines. All 
three CRISPR control clones were used as a reference (“REF”) in comparison to the six 
β1L-reduced clones (“TEST”). Genes with <1cpm/3 samples were discarded from the 
analysis prior to library size calculation. The Beyer-Hardwick Method was used to 
determine genes significantly altered between the “REF” and “TEST” with FDR<0.05. 
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Non-directional GO-TermFinder was used to determine GO-enriched processes for 
differentially expressed genes. GABPA-bound genes were determined from ENCODE 
GABPA ChIP-seq data for all available cancer cell lines 
(http://hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/wgEncodeRegTfbsClust
ered/wgEncodeRegTfbsClusteredV3.bed.gz). BEDOPS closest-features was used to 
determine transcription start sites within 3 kb of called GABPA peaks presented in ≥2 
samples. These transcription start sites are referred to “GABP-bound genes” throughout 
the text. 
 
siRNA and LNA-ASO knockdown 
Non-targeting, GABPB1, and GABPB2-directed siRNA pools were obtained from 
Dharmacon. Scrambled control and GABPB1L 3’ UTR-directed Locked Nucleic Acid 
Antisense Oligonucleotides (LNA-ASOs) were obtained from Exiqon. 100 µL of cells 
were seeded at a density of 30,000 cells/mL in a 96-well plate and transfected 24 hr 
after with a final concentration of 50 nM siRNA or 25 nM LNA-ASO and 0.1 uL of 
Dharmafect 1 reagent (Dharmacon). At 48 and 72 hr post-transfection, cells were lysed 
and cDNA was generated using the POWER SYBR Green Cells-to-Ct kit (Ambion). 
Quantitative PCR was performed to measure the expression levels of GUSB, TERT, 
GABPB1L, and GABPB2 as described below. All siRNAs and LNA-ASOs were 
independently validated at 48 and 72 hr post-transfection for >50% knockdown of target 
transcript in all cell lines. 
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RT-qPCR 
Quantitative PCR was performed with POWER SYBR Green Complete Master Mix 
(LifeTechnologies) to measure the expression levels of GUSB (forward primer: 
CTCATTTGGAATTTTGCCGATT; reverse primer: CCGAGTGAAGATCCCCTTTTTA), 
TERT (forward primer: TCACGGAGACCACGTTTCAAA; reverse primer: 
TTCAAGTGCTGTCTGATTCCAAT), GABPB1 (forward primer: 
TCCACTTCATCTAGCAGCACA; reverse primer: GTAATGGTGTTCGGTCCACTT), 
GABPB1L (forward primer: ATTGAAAACCGGGTGGAATC; reverse primer: 
CTGTAGGCCTCTGCTTCCTG), GABPB2 (forward primer: 
CGCCACCATCGAGATGTCG; reverse primer: TCCAGAGCTATGTCAAAGGCT), 
SKP2 (forward primer: ATGCCCCAATCTTGTCCATCT; reverse primer: 
CACCGACTGAGTGATAGGTGT), COXIV (forward primer: 
CAGGGTATTTAGCCTAGTTGGC; reverse primer: GCCGATCCATATAAGCTGGGA), 
EIF6 (forward primer: CCGACCAGGTGCTAGTAGGAA; reverse primer: 
CAGAAGGCACACCAGTCATTC), TFB1M (forward primer: 
GTTGCCCACGATTCGAGAAAT; reverse primer: GCCCACTTCGTAAACATAAGCAT), 
and RPS16 (forward primer: TCGGACGCAAGAAGACAGC; reverse primer: 
AGCAGCTTGTACTGTAGCGTG). Each sample was measured in triplicate on the 
Applied Biosystems 7900HT Fast Real-Time System. Melting curves were manually 
inspected to confirm PCR specificity. Relative expression levels were calculated by the 
deltaCT method against GUSB. 
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CRISPR-Cas9 editing 
Plasmids encoding spCas9 and sgRNAs were obtained from Addgene (Plasmids 
#41815 and #47108). Oligonucleotides for construction of sgRNAs were cloned into the 
sgRNA plasmid as previously described (Brown et al., 2016). Target sequences for 
sgRNAs are provided in Table S1. Targeting vectors PuroR TV and HygroR TV were 
acquired and incorporated at target loci as previously described (Gapinske et al., 2018). 
In brief, LN229, NHAPC5, HEK293T, HCT116, and T98G cells were transfected with 
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions in 24 well 
plates. GBM1 cells were transfected by electroporation using a Gene Pulser XCell 
(BioRad) in PBS at 140 Volts, 950 µF. Each cell line was transfected with equal 
amounts of Cas9, target sgRNA, targeting vector PuroR TV (GBM1, LN229, HCT116, 
HEK293T, and T98G) or HygroR TV (NHAPC5) and universal sgRNA. Cleaving of the 
targeting vector by the universal sgRNA-directed Cas9 allowed for integration of the 
PuroR or HygroR cassette at the control or GABPB1L target loci. Integration only occurs 
post-cutting of both the targeting vector and target genomic locus. Clonal populations 
were selected with Puromycin (0.5 µg/ml HCT116 and T98G, 1 µg/ml GBM1 and 
LN229, and 2 µg/ml HEK293T) or Hygromycin (0.5 µg/ml for NHAPC5). 
 
Analysis of on-target and off-target editing 
Analysis of on-target and off-target mutations was conducted as previously described 
(Gapinske et al., 2018). In brief, genomic DNA from each clone was isolated using the 
Animal Genomic DNA Purification Mini Kit (Earthox Life Sciences). PCRs to detect 
integration of the targeting vector at on-target or off-target sites were performed using 
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KAPA2G Robust PCR kits (Kapa Biosystems) according to the manufacturer’s 
instructions. The DNA sequences of the primers for each target are provided in Table 
S1. PCR products were visualized in 2% agarose gels and images were captured using 
a ChemiDoc-It2 (UVP). Indels at off-target sites were analyzed with the Surveyor 
Mutation Detection kit (IDT) by first amplifying the target locus using PCR with KAPA 
Robust2G DNA polymerase. The resulting PCR products were melted and re-annealed 
according to manufacturer’s instructions, and 18 µL of the reannealed duplex was mixed 
with 1µL of Surveyor Nuclease and 1 µL of Enhancer Solution and incubated at 42° 
Celsius for 1 hr. Final product was loaded onto a 10% TBE polyacrylamide gel and run 
at 200 V for 30 min. The gels were stained with ethidium bromide and visualized using a 
ChemiDoc-It2 (UVP). On-target editing of GABPB1L (Figure S2A) or control locus 
(Figure S3B) was evaluated by PCR to detect the integration of the targeting vector. 
DNA sequencing of the alleles without integration was used to detect indels (Figure 
S2B). Analysis of off-target mutations was performed by testing integration of the 
targeting vector at predicted off-target sites (Hsu et al., 2013) in coding regions for each 
sgRNA used in each cell line (Figures S3A and S3D-F). For predicted off-target sites 
within coding sequences we performed Surveyor assays to detect indels (Figure S3C). 
 
Immunoblotting 
Immunoblotting for Cyclophilin B (loading control) and GABPβ1 (GABPβ1S and 
GABPβ1L) was performed using a rabbit anti-Cyclophilin B antibody PA1-027A (Pierce 
antibodies; 1:1,000 dilution) and rabbit anti-GABPβ1 antibody 12597-1-AP (Proteintech; 
1:500 dilution) using the NuPAGE system (Thermofisher), according to the provider’s 
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instructions. Detection of primary bands was done using the Li-Cor goat anti-rabbit 
680RD secondary antibody (1:15,000 dilution) on the Li-Cor Odyssey Fc imaging 
system. 
 
NanoBiT protein-protein interaction assay 
Full-length GABPB1L or GABPB1S was cloned into either the pBiT1.1-C [TK/LgBiT] or 
pBiT2.1-C [TK/LgBiT] vectors (Promega; N196A and N197A, respectively) using In-
Fusion HD Cloning (Takara). In accordance with the manufacturer’s instructions, the 
QuikChange Lightning Site-Directed Mutagenesis kit (Agilent) was used to introduce 
three separate deletions (DEL1-3) into the pBiT1.1-C-GABPB1L vector (see Table S3 
for mutagenesis primers). Mutagenized plasmids were validated using Sanger 
sequencing and purified for use in the NanoBiT assay. Prior to use, 1 volume NanoBiT 
vector was diluted into 3 volumes of pCMV6-Neo control vector (OriGene) to a final 
volume of 10 ng/µL. 100 µL of LN229 or NHAPC5 cells were seeded at a density of 
30,000 cells/mL in 96-well plates 24 hr prior to transfection. Cells were transfected with 
a total of 100 ng of plasmid DNA and 0.3 µL X-tremeGENE HP DNA Transfection 
Reagent (Roche) according to manufacturer’s instructions. The following combinations 
were used to assay GABPβ1L tetramer formation in LN229 and NHAPC5 cells: 
  POS: pBiT1.1-C-GABPB1L-WT + pBiT-2.1-C-GABPB1L 
  NEG: pBiT1.1-C-GABPB1L-WT + pBiT-2.1-C-GABPB1S 
  DEL1: pBiT1.1-C-GABPB1L-DEL1 + pBiT-2.1-C-GABPB1L 
  DEL2: pBiT1.1-C-GABPB1L-DEL2 + pBiT-2.1-C-GABPB1L 
DEL3: pBiT1.1-C-GABPB1L-DEL3 + pBiT-2.1-C-GABPB1L 
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24 hr following transfection, Nano-Glo® Live Cell Substrate diluted in Nano-Glo® LCS 
Dilution Buffer (Promega; N205A and N206A, respectively) was added directly to the 
cells and luminescence was assayed 1 hr later on a GloMax® 96 MicroPlate 
Luminometer (Promega) according to manufacturer’s instructions. All data were 
normalized to the positive control (POS) for each cell line. 
 
Cell proliferation and viability assays 
100 µL of cells were seeded at a density of 5,000 cells/mL in 96-well plates. At t=0, 48 
and 96 hr post-seeding, MTS (Cell titer 96 aqueous MTS, Promega) was incubated for 2 
hr at 37º Celsius in a ratio of 1:5 in media, according to manufacturer’s instructions. 
Plate was read on the Bioplate Synergy 2 microplate reader at 490 nm. Cell proliferation 
of individual samples was calculated by normalizing absorbance to their corresponding 
absorbance at t=24 hr. Each time point was analyzed in triplicates. For cell viability, 
cells were trypsinized, collected and counted on a hemocytometer with trypan-blue 
exclusion approximately every 7 days from day 33 to day 102 post-editing, or until the 
minimal sensitivity limits of the assay were reached. Between viability time points, cells 
were split prior to confluency and replated at 1/8th density to ensure consistent growth 
conditions. The ratio between viable and dead cells was used to determine cell viability. 
It is important to note that trypsinization of cells undergoing telomere dysfunction may 
have influenced to the viability phenotype in the GBM1 and T98G clones after day 85 
post- editing. 
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Chromatin immunoprecipitation 
Chromatin immunoprecipitation (ChIP) for GABPα was performed using the ActiveMotif 
High Sensitivity kit. In brief, GBM1, T98G, HCT116, and HEK293T CRISPR controls 
and GABPβ1L-reduced clones were grown to 80% confluency in 15 cm plates and fixed 
with 4% formaldehyde. Chromatin was sonicated to a size range of 200-1200 bp by the 
Diagenode Biorupter. 12-18 µg of chromatin was used per GABPα (Santa Cruz 
Biotechnology: sc-22810) and IgG control (Cell Signaling: 2729) immunoprecipitation for 
each cell type. Enrichment at the TERT promoter was determined by qPCR with the 
ssoAdvanced Universal SYBR Green Supermix (Biorad) supplemented with Resolution 
Solution from GC-RICH PCR System (Roche). The following primer set was used for 
qPCR: TERT+47 (forward: 5’-GCCGGGGCCAGGGCTTCCCA-3’; reverse: 5’ 
CCGCGCTTCCCACGTGGCGG-3’; Tm=74° Celsius). PCR was carried out on the 
Applied Biosystems 7900HT Fast Real-Time System. Three replicate PCR reactions 
were carried out for each sample. 
 
Telomere length measurement 
All telomere length measurements were conducts using the telomere qPCR protocol 
initially described in Cawthon 2002 (Cawthon, 2002) and later modified in Lin et al. 2009 
(Lin et al., 2010). DNA was collected from CRISPR control and β1L-reduced cell lines at 
days 33, 44, 61, 78, and 83 post-CRISPR-Cas9 editing using 
Phenol:Chloroform:Isoamyl Alcohol (Invitrogen) according to manufacturer’s 
instructions. DNA was diluted to a final concentration of 2 ng/µL prior to analysis. 
Telomere length was measured by qPCR with POWER SYBR Green master mix on the 
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Applied Biosystems 7900HT Fast Real-Time System using the following telomere (TEL) 
and single gene control (SGC) primer sets: TEL-qPCR, primer forward: 
CGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT, primer reverse: 
GGCTTGCCTTACCCTTACCCTTACCCTTACCCTTACCCT; SGC-qPCR, primer 
forward: CAGCAAGTGGGAAGGTGTAATCC primer reverse: 
CCCATTCTATCATCAACGGGGTACAA (Cawthon, 2002; Lin et al., 2010; Xie et al., 
2015). The following PCR conditions were used: 95° Celsius for 10 min followed by 40 
cycles of data collection at 95° Celsius for 15 s, 60° Celsius anneal for 30 s and 72° 
Celsius extend for 30 s along with 80 cycles of melting curve from 60° Celsius to 95° 
Celsius. Relative telomere length was determined as the linear relationship between 
TEL and SGC (T/S). Three independent RT-qPCR reactions were carried out for each 
sample, with each independent experiment performed on distinct days with distinct 
populations of cells. 
 
Exogenous GABPβ1L and TERT overexpression 
GABPB1L human cDNA (OriGene) was cloned into pCMV6-Neo Vector (OriGene) 
using the Cold Fusion Cloning Kit (System Biosciences) according to manufacturer’s 
instructions. The pCMV6-Neo-GABPB1L plasmids obtained were validated by Sanger 
sequencing using the manufacturer’s primers. 2 µg pCMV6-Neo (empty vector, for 
control purposes), pCMV6-Neo-B1L or pCI-Neo-hEST2 (Addgene) were transfected into 
each GBM1, T98G, and LN229 CRISPR control clone (CTRL) or GABPβ1L-reduced 
clone (C1 and C2) using 6 µL X-tremeGENE HP DNA Transfection Reagent (Roche) 
according to producer’s instructions at day 61 (GBM1 and T98G) or day 58 (LN229) 
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post-editing. C1/C2 and β1L/TERT refers to the clone number and cDNA transfected, 
respectively. Overexpression of exogenous GABPβ1L and TERT mRNA was confirmed 
by RT-qPCR as described above. Clones were maintained in 100 µg/mL G418 
(Invivogen) and validated for continued GABPB1L and TERT expression three weeks 
post-transfection. Lentiviral TERT rescue is described above under the “Orthotopic 
xenografting and in vivo bioluminescent imaging” subheading. pCI neo-hEST2 was a 
gift from Robert Weinberg (Meyerson et al., 1997) (Addgene plasmid # 1781). 
 
Fluorescent imaging and quantification 
CTRL and GABPβ1L-reduced clones were seeded at a density of 25,000 cells/mL on 
day 70 post-editing. Cells were fixed in 4% formaldehyde and permeabilized in 100% 
methanol before co-staining with DAPI and anti-γH2AX AF647 conjugated antibody 
(EMD Millipore 05-636-AF647) at 4° Celsius overnight. All images were taken at 63x 
magnification on an AxioImager M1 upright fluorescent microscope (Zeiss) with 2.8 ms 
exposure. Post-processing and signal normalization of images was done using the on-
board ZEN2 software. Quantification of extent of chromatin bridge formation and giant 
cell micronucleation was performed as follows: each slide was assigned a randomized 
number to blind the quantifier prior to counting. Ten computationally randomized unique 
40x fields of view with a cell number of n>20 were used per slide. For each field of view, 
total cell number, number of chromatin bridges, and number of giant micronucleated 
cells were counted. Only nuclei completely in the field of view were counted. A 
chromatin bridge was defined as a solid strand of nuclear material linking two distinctly 
independent nuclei. Two nuclei linked by a chromatin bridge were counted as one cell. 
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A giant micronucleated cell was defined as a single cell containing n≥5 uncondensed 
nuclei. The weighted proportion of chromatin bridges and giant micronucleated cells 
was determined per field of view and summed into an aggregate proportion. All methods 
and quantifications were verified using the same parameters as described above by an 
independent party. Quantification of γH2AX was performed similarly to chromatin bridge 
and giant cell micronucleation counting with the following differences: n>10 cells per 
field of view was used as a threshold and individual visible γH2AX foci were counted per 
cell per field of view. This procedure was likewise followed to quantify LN229 clones at 
day 45 and day 61 post-editing (n=4 fields of view). 
 
Flow cytometry 
On day 75 post-editing, 300,000 cells/line were stained with a combination of Hoechst® 
33342 (Thermofisher; 10 ng/mL), AnnexinV-PE (BD Biosciences #51-65875X; 1:1,000 
dilution), and C-12-FDG (Setareh Biotech; 33 µM final concentration) for 45 min at 37° 
Celsius in the dark. Samples were run for 10,000 counts on a Sony SH800 cytometer 
and analyzed on FlowJo®. The same gating strategy was used for all experiments. All 
data were collected ONLY after a stable flow of cells had been established. Then, FSC-
A vs. FSC-H gating was used to select for singlets along the positive diagonal. Next, 
FSC-A vs. SSC-A gating was used to remove all cellular debris (FSC-A/SSC-A low 
particles). Finally, non-specific antibody/fluorophore uptake was used to gate against 
dead cells with compromised membranes. 
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4.3 QUANTIFICATION AND STATISTICAL ANALYSIS 
All statistical analysis was done using GraphPad Prism 7. Non-parametric Spearman 
correlation was used for GABP isoforms versus TERT and telomere length versus 
viability analysis (α=0.05). Adjusted p values after multiple comparison correction are 
reported for each correlation. A non-parametric Spearman correlation was chosen due 
to the failure of a subset of data sets to meet the homoscedasticity assumption of the 
Pearson test. Mouse survival data for the orthotopic xenograft experiments were 
analyzed with the Kaplan-Meier Log-Rank Test (α=0.05). The non-parametric Welch’s t-
test was used as listed for samples with unequal sample sizes (α=0.05). A two-sided 
heteroscedastic Student’s t-test was used as listed for all other assays (α=0.05) after 
confirming differences in variances between tested groups. All error bars shown are 
mean ± S.D. A sample size of 3 independent experiments (biological replicates) was 
used for all experiments, unless otherwise noted, in order to ensure appropriate 
statistical power to detect a statistically significant change of at least two-fold. 3 
technical replicates per biological replicate were used for each experiment as noted. 
 
4.4 DATA AND SOFTWARE AVAILABILITY 
All data used for GABP isoform and TERT expression correlations are available for 
public access from the TCGA (level 3 normalized data, December 2015, http://tcga-
data.nci.nih. gov/tcga/dataAccessMatrix.htm). All raw data used for RNA-seq analysis 
has been deposited in the European Genome Archive (EGA) under ID code 
EGAS0000100258.2. Scripts used for RNA-seq analysis are available at 
https://github.com/UCSF-Costello-Lab/Tert-gabp. 
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4.5 KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Cyclophilin B Pierce antibodies PA1-027A 
GABPB1 Proteintech 12597-1-AP 
Goat anti-rabbit secondary antibody Li-Cor 680RD 
GABPα Santa Cruz Biotechnology sc-22810 
IgG Cell Signaling 2729 
REAGENT or RESOURCE SOURCE IDENTIFIER 
γH2AX AF647 EMD Millipore 05-636-AF647 
Bacterial and Virus Strains 
Firefly Luciferase Lentifect™ Purified 
Lentiviral Particles Genecopoiea 
LPP-FLUC-
Lv105 
Biological Samples 
   
Chemicals, Peptides, and Recombinant Proteins 
Dharmafect 1 Dharmacon T-2001-02 
POWER SYBR Green Complete Master Mix Applied Biosystems 4367659 
Lipofectamine 2000 Invitrogen 11668-030 
Puromycin Millipore-Sigma P8833 
Hygromycin B Solution Omega Scientific HG-80 
KAPA Robust2G DNA polymerase KAPA KK5023 
In-Fusion HD Cloning Plus Takara 638910 
X-tremeGENE HP DNA Transfection Reagent Roche 06366546001 
Nano-Glo® Live Cell Substrate Promega N205A 
Nano-Glo® LCS Dilution Buffer Promega N206A 
Cell titer 96 aqueous MTS Promega G3581 
Formaldehyde Sigma F8775 
ssoAdvanced Universal SYBR Green 
Supermix Biorad 1725270 
Resolution Solution from GC-RICH PCR 
System Roche 19024024 
Phenol:Chloroform:Isoamyl Alcohol Invitrogen 15593-031 
TRIzol LifeTechnologies 15596018 
Methanol Sigma 179337 
VECTASHIELD Antifade Mounting Medium 
with DAPI 
Vector 
Laboratories H-1200 
Hoechst® 33342 Thermofisher 62249 
AnnexinV-PE BD Biosciences 556421 
C-12-FDG Setareh Biotech 7188 
D-Luciferin GoldBio LUCK-100 
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REAGENT or RESOURCE SOURCE IDENTIFIER 
Critical Commercial Assays 
KAPA Stranded mRNA-Seq kit KAPA Biosystems KK8421 
Power SYBR Green Cells-to Ct kit Ambion 4402953 
In-Fusion HD Cloning Takara 121416 
QuikChange Lightning Site-Directed 
Mutagenesis Agilent 210518 
ChIP-IT High Sensitivity® ActiveMotif 53040 
Cold Fusion Cloning Kit System Biosciences MC010B-1 
Surveyor Mutation Detection IDT 706025 
Deposited Data 
RNA-seq data European Genome Archive (EGA) 
EGAS00001002
58.2 
Scripts  
https://github.co
m/UCSF-
Costello-
Lab/Tert-gabp 
Experimental Models: Cell Lines 
GBM1 Bell et al., 2015 N/A 
T98G ATCC ATCC CRL-1690 
LN229 ATCC ATCC CRL-2611 
HEK293T ATCC ATCC CRL-3216 
NHAPC5 Ohba et al., 2016 N/A 
HCT116 ATCC ATCC CRL-247 
SF10417-GNS Costello Lab N/A 
SF7996-GNS Costello Lab N/A 
SF8249 Costello Lab N/A 
SF9030 Costello Lab N/A 
SF11411 Costello Lab N/A 
LN18 ATCC CRL-2610 
hNPCs Xu et al., 2016 N/A 
Experimental Models: Organisms/Strains 
Mice / athymic (nu/nu) Simonsen Laboratories 
Sim:(NCr) nu/nu 
fisol 
Mice / athymic (nu/nu) Envigo (formerly Harlan) 
Hsd:Athymic 
Nude Foxn1nu 
Oligonucleotides 
Genomic editing: See Table S1   
GUSB forward: 
CTCATTTGGAATTTTGCCGATT Bell et al., 2015 N/A 
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REAGENT or RESOURCE SOURCE IDENTIFIER 
GUSB reverse: 
TTCAAGTGCTGTCTGATTCCAAT Bell et al., 2015 N/A 
TERT forward: 
TCACGGAGACCACGTTTCAAA This paper N/A 
TERT reverse: 
TTCAAGTGCTGTCTGATTCCAAT This paper N/A 
GABPB1 forward: 
TCCACTTCATCTAGCAGCACA This paper N/A 
GABPB1 reverse: 
GTAATGGTGTTCGGTCCACTT This paper N/A 
GABPB1L forward: 
ATTGAAAACCGGGTGGAATC This paper N/A 
GABPB1L reverse: 
CTGTAGGCCTCTGCTTCCTG This paper N/A 
GABPB2 forward: 
CGCCACCATCGAGATGTCG This paper N/A 
GABPB2 reverse: 
TCCAGAGCTATGTCAAAGGCT This paper N/A 
SKP2 forward: 
ATGCCCCAATCTTGTCCATCT This paper N/A 
SKP2 reverse: 
CACCGACTGAGTGATAGGTGT This paper N/A 
COXIV forward: 
CAGGGTATTTAGCCTAGTTGGC This paper N/A 
COXIV reverse: 
GCCGATCCATATAAGCTGGGA This paper N/A 
EIF6 forward: 
CCGACCAGGTGCTAGTAGGAA This paper N/A 
EIF6 reverse: 
CAGAAGGCACACCAGTCATTC This paper N/A 
TFB1M forward: 
GTTGCCCACGATTCGAGAAAT This paper N/A 
TFB1M reverse: 
GCCCACTTCGTAAACATAAGCAT This paper N/A 
RPS16 forward: 
TCGGACGCAAGAAGACAGC This paper N/A 
RPS16 reverse: 
AGCAGCTTGTACTGTAGCGTG This paper N/A 
TERT+47 forward: 
GCCGGGGCCAGGGCTTCCCA Bell et al. 2015 N/A 
TERT+47 reverse: 
CCGCGCTTCCCACGTGGCGG Bell et al. 2015 N/A 
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REAGENT or RESOURCE SOURCE IDENTIFIER 
TEL forward: 
CGGTTTGTTTGGGTTTGGGTTTGGGTTTG
GGTTTGGGTT 
Cawthon, 2002; 
Lin et al., 2010; 
Xie et al., 2015 
N/A 
TEL reverse: 
GGCTTGCCTTACCCTTACCCTTACCCTTA
CCCTTACCCT 
Cawthon, 2002; 
Lin et al., 2010; 
Xie et al., 2015 
N/A 
SGC forward: 
CAGCAAGTGGGAAGGTGTAATCC 
Cawthon, 2002; 
Lin et al., 2010; 
Xie et al., 2015 
N/A 
DEL1 forward: 
GCCTCTGCTTCCTGTTTCTTTAGGAGCTG
CTGT 
This paper N/A 
DEL1 reverse: 
ACAGCAGCTCCTAAAGAAACAGGAAGCAG
AGGC 
This paper N/A 
DEL2 forward: 
GCAGAGGCCTACAGACAGTTGGAAGCTAT
GAC 
This paper N/A 
DEL2 reverse: 
GTCATAGCTTCCAACTGTCTGTAGGCCTC
TGC 
This paper N/A 
DEL3 forward: 
GTCATAGCTTCCAACTGTAGGCCTCTGCT
TCC 
This paper N/A 
DEL3 reverse: 
GGAAGCAGAGGCCTACAGTTGGAAGCTAT
GAC 
This paper N/A 
Recombinant DNA 
siRNA Non-targeting Dharmacon D-001206-13 
siGABPB1 Dharmacon L-013083-00 
siGABPB2 Dharmacon M-016074-00 
LNA Scramble control: 
TTTAAGCCGATGCGTT Exiqon 300603-00 
LNA GABPB1L 3' UTR: 
CTAACCAACAACGATC Exiqon 300603-00 
spCas9 Addgene #41815 
sgRNAs Addgene #47108 
pBiT1.1-C [TK/LgBiT] Promega N196A 
pBiT2.1-C [TK/LgBiT] Promega N197A 
pBiT1.1-C-GABPB1L-WT/DEL1/DEL2/DEL3 This paper N/A 
pBiT-2.1-C-GABPB1L This paper N/A 
pBiT-2.1-C-GABPB1S This paper N/A 
pCMV6-Neo control vector OriGene PCMV6NEO 
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REAGENT or RESOURCE SOURCE IDENTIFIER 
pCMV6-Neo-GABPB1L This paper N/A 
Software and Algorithms 
R v1.7.1 R Project 
https://cran.r-
project.org/mirro
rs.html 
TopHat v.2.0.14 
https://doi.org/10.1
186/gb-2013-14-4-
r36 
https://ccb.jhu.e
du/software/top
hat/index.shtml 
GENCODE V19 GENCODE 
https://www.gen
codegenes.org/r
eleases/19.html 
edgeR v3.7 
https://doi.org/10.1
8129/B9.bioc.edge
R 
https://biocondu
ctor.org/packag
es/release/bioc/
html/edgeR.html 
GO-TermFinder v0.86 
https://doi.org/10.1
093/bioinformatics/
bth456 
 
https://metacpa
n.org/release/G
O-TermFinder 
BEDOPS v.2.4.32 
https://doi.org/10.1
093/bioinformatics/
bts277 
https://bedops.r
eadthedocs.io/e
n/latest/ 
FlowJo v10 FlowJo, LLC 
https://www.flow
jo.com/solutions
/flowjo/downloa
ds 
Prism v7 GraphPad 
https://www.gra
phpad.com/how
-to-buy/ 
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5.1 CONTRIBUTION TO FIELD OF TUMOR IMMORTALITY 
 Telomerase reactivation occurs in more than 90% of human cancers and is 
fundamental for tumor cell immortalization. While the occurrence of TERT promoter 
mutations early in GBM evolution suggests they are important for tumorigenesis, their 
role in maintaining telomere length, replicative immortality, and cell viability at later time 
points has been relatively unexplored. We have identified the tetramer-forming 
GABPβ1L isoform of GABP to be a necessary component for full activation of the 
mutant TERT promoter and replicative immortality in TERT promoter mutant, but not 
wild-type, GBM cells. These results add to recent studies showing that TERT promoter 
mutations are necessary but not sufficient for cellular immortalization in TERT promoter 
mutant tumor cells (Chiba et al., 2017; Li et al., 2015). Our results also suggest binding 
of the GABPβ1L-containing GABP tetramer to the mutant TERT promoter is necessary 
to maintain maximal expression of TERT. 
  
5.2 CAVEATS, CONSIDERATIONS, AND FUTURE DIRECTIONS 
 Telomere shortening and loss of cellular proliferation has been previously 
observed in brain tumor cultures after sustained inhibition of telomerase (Barszczyk et 
al., 2014; Castelo-Branco et al., 2011; Marian et al., 2010). One difference with these 
studies and ours is that in addition to potently reducing the expression of TERT, our 
GABPβ1L-reduced clones had concomitant deregulation of a subset of GABP-regulated 
genes that may influence the observed TERT-dependent phenotypes. Although 
overexpression of exogenous TERT rescued cell growth of the cells with reduced 
GABPβ1L function, expression of TERT at more physiologic levels through activation of 
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the endogenous wild-type TERT allele may allow for more precise analysis of 
phenotypes. Thus, we cannot fully rule out that other GABPβ1L target genes may 
contribute to the in vitro and in vivo phenotypes we observed. 
 The growth decrease occurring as early as 48 hr after LNA-ASO-mediated 
knockdown of GABPβ1L raises the possibility that, in addition to the gradual and 
protracted loss of viability, GABPβ1L and TERT reduction also could have immediate 
effects. As telomere length is heterogeneous within tumor cell cultures (der-Sarkissian 
et al., 2004; Wang et al., 2013), cells with shorter telomeres may be more vulnerable 
upon reduction in TERT expression. Conversely, we expect that the subset of GBM 
cells with longer telomeres – and not those with critically short telomeres – would 
preferentially survive through the cell expansion required to establish the clonal cultures 
of GABPβ1L-reduced cells, and then succumb to gradual decreases in telomere length 
at later time points.  
 Overall this ongoing process could contribute to the gradual loss of viability 
detected in the bulk population assays. The more immediate effect in our LNA-ASO cell 
experiments is consistent with an acute telomere-mediated cell death phenotype in 
NRAS-mutant melanoma due to dependence on TERT expression from the mutant 
promoter (Reyes-Uribe et al., 2018). However, due to the limitations of our CRISPR-
Cas9 experimental design and focus on later time points, further studies to investigate 
the mechanism of immediate cellular effects following reduction - or elimination - of 
GABPβ1L function in TERT promoter mutant GBM will require inducible systems and 
single-cell analysis. 
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 GABPβ1L tetramerization activity and TERT expression were reduced but not 
eliminated in our experiments. Attempts to further suppress TERT mRNA expression in 
the GABPβ1L-reduced clones through LNA-ASO-mediated knockdown of GABPβ1L 
had no effect. Therefore, a low level of expression of TERT from the mutant promoter 
may be maintained independent of GABPβ1L function. Although our data strongly 
support GABPβ1L as the main driver of TERT expression from the mutant promoter and 
the primary factor enabling cell immortality in TERT promoter mutant GBM, they also 
support the existence of a secondary mechanism contributing to the overall TERT 
expression level in TERT promoter mutant tumor cells. Secondary mechanisms could 
involve an activating structural change in the mutant TERT promoter G-quadruplex or 
activation through recruitment of other ETS factors (Chaires et al., 2014; Li et al., 2015; 
Lim et al., 2010; Makowski et al., 2016).  
 Additionally, the GABP tetramer-forming isoform GABPβ2 may be able to 
partially activate TERT expression at the mutant TERT promoter. GABPβ2 knockdown 
significantly reduced TERT expression levels in a subset of TERT promoter mutant 
GBM lines. However, the absence of a positive correlation between GABPB2 and TERT 
expression levels in glioma tissue samples and the near total loss of the occupancy of 
GABP at the mutant TERT promoter after disruption of GABPβ1L suggest that GABPβ2 
plays a more minor role, at least when GAPβ1L is present. We cannot however exclude 
the possibility that GABPβ2 plays a role in regulating the mutant TERT promoter in a 
small subset of cells. Therefore, to fully eliminate TERT expression in TERT promoter 
GBM, it may be necessary to jointly inhibit GABPβ1L alongside one or more secondary 
mechanisms of TERT expression. 
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5.3 GABPβ1L AS A THERAPEUTIC TARGET IN CANCER  
 Overall, the present study gives credence to GABPβ1L as a potential therapeutic 
target for tumor cells with the mutant TERT promoter. GABP is recruited to the mutant 
TERT promoter in multiple cancer types (Akincilar et al., 2016; Bell et al., 2015; Stern et 
al., 2015) and therefore may be universal therapeutic target for TERT promoter mutant 
tumors.  
 The prevalence of identical TERT promoter mutations across a large number of 
cancer types (Bell et al., 2016; Zehir et al., 2017) highlights the potentially widespread 
role of the GABPβ1L-containing GABP tetramer as a dominant factor responsible for 
enabling replicative immortality in cancer. This is particularly relevant as direct 
telomerase inhibitors block tumor cell immortality, but can also affect TERT in normal 
stem and germ cells (Jager and Walter, 2016; Shay and Wright, 2006). Although GABP 
is a transcription factor, it is an intriguing target due to its dual function as a dimer and 
tetramer. GABPβ1L is not required for normal development in mice, and in GBM cells 
the majority of GABP target genes do not seem to be as sensitive to reduction of 
GABPβ1L compared to the mutant TERT promoter. Thus, inhibiting the dispensable 
tetramer-forming GABPβ1L isoform while leaving the dimer and other cell-essential 
GABP isoforms unperturbed could be a viable strategy to block cellular immortality in 
TERT promoter mutant tumors, including glioma. 
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